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Abstract 
Immune therapies have significantly improved outcomes for cancer patients with 
poor prognosis, but mechanisms that underlie response or resistance to therapy remain 
elusive. Inflammatory cytokines such as interferon-gamma (IFNG) augment immune 
function yet also promote T cell exhaustion through inhibitory ligands such as PDL1. How 
these opposing effects are integrated in the tumor microenvironment is unclear. We show 
that while inhibiting tumor IFNG signaling decreases interferon-stimulated genes (ISGs) 
in cancer cells, it increases ISGs in immune cells by enhancing IFNG produced by 
exhausted T cells (TEX). In tumors with favorable antigenicity, these TEX mediate rejection. 
In tumors with neoantigen or MHC-I loss, TEX instead utilize IFNG to drive maturation of 
innate immune cells, promoting tumor clearance. Thus, interferon signaling in cancer cells 
and immune cells oppose each other to establish a regulatory relationship that limits both 
adaptive and innate immune killing. In melanoma and lung cancer patients, perturbation 
of this relationship is associated with response to immune checkpoint blockade 
independent of tumor mutational burden. 
In addition to these suppressive mechanisms, tumor infiltration and antigen loss 
are common mechanisms that limit effectiveness of T cell responses in solid tumors, in 
particular chimeric antigen (CAR) T cells. Delivery of pattern recognition receptor agonists 
is one strategy to improve immune infiltration and prime adaptive immunity; however, 
targeting these agonists to immune cells is challenging, and off-target signaling in cancer 
cells can be detrimental as described above. Here, we engineer murine CAR-T cells to 
deliver RN7SL1, an endogenous RNA that activates RIG-I/MDA5-dependent interferon 
signaling. RN7SL1 is deployed in extracellular vesicles and preferentially transferred to 
intratumoral immune cells. Unlike other RNA agonists, RN7SL1 restricts development of 
myeloid-derived suppressor cells and decreases TGFB expression. In dendritic cells, it 
fosters DC subsets with anti-viral and costimulatory features. Consequently, endogenous 
effector-memory CD8 T cells expand, while exhausted T cells contract. Armed with the 
ability to activate endogenous immune responses, these CAR-T cells effectively reject 
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Immune therapies have significantly improved outcomes for cancer patients with 
poor prognosis, but mechanisms that underlie response or resistance to therapy remain 
elusive. Inflammatory cytokines such as interferon-gamma (IFNG) augment immune 
function yet also promote T cell exhaustion through inhibitory ligands such as PDL1. How 
these opposing effects are integrated in the tumor microenvironment is unclear. We show 
that while inhibiting tumor IFNG signaling decreases interferon-stimulated genes (ISGs) 
in cancer cells, it increases ISGs in immune cells by enhancing IFNG produced by 
exhausted T cells (TEX). In tumors with favorable antigenicity, these TEX mediate rejection. 
In tumors with neoantigen or MHC-I loss, TEX instead utilize IFNG to drive maturation of 
innate immune cells, promoting tumor clearance. Thus, interferon signaling in cancer cells 
and immune cells oppose each other to establish a regulatory relationship that limits both 
adaptive and innate immune killing. In melanoma and lung cancer patients, perturbation 
of this relationship is associated with response to immune checkpoint blockade 
independent of tumor mutational burden. 
In addition to these suppressive mechanisms, tumor infiltration and antigen loss 
are common mechanisms that limit effectiveness of T cell responses in solid tumors, in 
particular chimeric antigen (CAR) T cells. Delivery of pattern recognition receptor agonists 
is one strategy to improve immune infiltration and prime adaptive immunity; however, 
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targeting these agonists to immune cells is challenging, and off-target signaling in cancer 
cells can be detrimental as described above. Here, we engineer murine CAR-T cells to 
deliver RN7SL1, an endogenous RNA that activates RIG-I/MDA5-dependent interferon 
signaling. RN7SL1 is deployed in extracellular vesicles and preferentially transferred to 
intratumoral immune cells. Unlike other RNA agonists, RN7SL1 restricts development of 
myeloid-derived suppressor cells and decreases TGFB expression. In dendritic cells, it 
fosters DC subsets with anti-viral and costimulatory features. Consequently, endogenous 
effector-memory CD8
+
 T cells expand, while exhausted T cells contract. Armed with the 
ability to activate endogenous immune responses, these CAR-T cells effectively reject 
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CHAPTER 1 - INTRODUCTION 
Section 1.1 – Immunobiology of Cancer 
 
The advent of immune-based therapies for the treatment of cancer has revolutionized 
patient outcomes in some highly refractory cancers. This is the realization of a concept 
famously pioneered by William Coley in the 19
th
 century (Coley, 1991); and more recently 
carried forward by pioneers around the world focused on T cell growth factors, adoptive T 
cell therapies, and T cell checkpoint inhibitors (Riley et al., 2019). At a more fundamental 
level, these translational efforts have built on a foundation of basic research investigating 
the role of immunity in the context of cancer. This includes a role for T cells, ILC1/NK cells, 
Dendritic cells, Monocyte/Macrophages, and others. 
 
Section 1.1.1 CD8+ T cells in Tumor Immunity 
CD8
+
 T cells are the most well characterized anti-tumor effector immune cell described to 
date. These cells function to recognize and eliminate cells in the body that express non-
self proteins. Generally, this occurs in the context of viral or bacterial infection in which 
infected cells alert CD8
+
 T cells to infection through presentation of non-self peptide 
fragments on the cell surface. In the context of cancer, this occurs through the recognition 
of “neoantigens” presented via the MHC-I complex (HLA-A, B, C in humans) by the T cell 
receptor (TCR). Briefly, tumors arise from healthy cells in which mutations cause aberrant 
growth. These genomic mutations lead to the production of mutant proteins that are not a 
part of the natural self-repertoire on which CD8+ T cells are selected.  Therefore, they are 
able produce immunogenic antigens that are recognized as “non-self” by CD8
+
 T cells in 
some cases (Durgeau et al., 2018; Schumacher and Schreiber, 2015). Notably, peptide 
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affinity for the MHC-I complex (Roudko et al., 2020), and relative difference from the wild-
type protein (Richman et al., 2019) are important determinants for T cell recognition of 
neoantigens. As these peptides arise from genomic mutations, there is a natural 
correlation between tumor immunogenicity and mutational burden (Cristescu et al., 2018; 
Hellmann et al., 2018; McGranahan et al., 2016; Riaz et al., 2017). Unsurprisingly then, 
immunotherapeutic strategies relying on the activation of these cells have seen the most 
success in tumor types with high levels of mutational burden such as melanoma and non-
small cell lung cancer (NSCLC) (Reck et al., 2016; Wolchok et al., 2013). 
Mutational burden and neoepitope recognition are not the only defining determinants of 
CD8
+
 T cell activation in the tumor microenvironment (TME). T cells are activated and 
regulated by three important signals: Signal 1 being TCR recognition of a cognate 
peptide/MHC complex (in this case a neoantigen), Signal 2 being the ligation of 
costimulatory molecules such as CD28 and 41BB, and Signal 3 being the recognition of 
soluble cues such as IL-12 and Type I IFN (Chen and Flies, 2013; Curtsinger and 
Mescher, 2010; Smith-Garvin et al., 2009). Much research has elucidated the importance 
of signals 2 and 3 in the TME and ways in which tumor cells dampen CD8
+
 T cell activation 
by limiting the strength of these signals. 
TCR recognition of a cognate antigen induces the formation of an immune synapse that 
aggregates many relevant surface receptors and facilitates important interactions of the 
cytoplasmic portion of these proteins. The main consequence of these cytoplasmic 
interactions is the initiation of a phosphorylation signaling cascade initiated by the CD3 
protein, particularly the zeta chain (Jordan and Koretzky, 2010). Aggregation of this co-
receptor initiates a well characterized signaling cascade that includes phosphorylation of 
Lck, Zap70, Slp76, and PI3K among others. This is dependent on relevant costimulatory 
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receptors such as CD28 that also participate in this interaction at the immune synapse 
(Jordan and Koretzky, 2010). The end result of this cascade is the activation of NF-kappaB 
(NFkB) signaling and calcium flux that initiates gene programs for T cell activation and 
expansion. However, negative costimulatory molecules are also expressed on CD8
+
 T 
cells. These include receptors such as PD1, Tim3, Lag3, and CTLA4, among others. 
These receptors function in various ways, but all converge on a function of limiting these 
signaling cascades, and therefore dampening T cell activation. The balance of these 
positive and negative signals, along with the strength of Signals 1 and 3 determines the 
strength and magnitude of anti-tumor CD8
+
 T cell responses (Chen and Flies, 2013). 
Signal 3 shapes the CD8
+
 T cell response by integrating soluble cues present in the local 
environment. In the context of viral infection these cues are often inflammatory in nature 
(e.g. IL-12, Type I IFN) and signal through respective receptor complexes that generally 
converge on the STAT4 transcription factor in CD8
+
 T cells (Crouse et al., 2015). This 
drives a transcriptional program for CD8
+
 T cells that includes differentiation into effector 
cells able to recognize and kill target cells through the lytic Granzyme family of molecules 
and the pore-forming protein Perforin (Halle et al., 2017). However, in contexts such as 
wound-healing and tumorigenesis, suppressive Signal 3 cytokines such as TGF-beta 
(TGFB) may predominate. This activates an opposing transcriptional program in T cells 
through the SMAD family of transcription factors, and converges on programs of tolerance 
instead of effector function. In this case, the CD8
+
 T cell response is again dampened, and 
is frequently compromised in the context of anti-tumor immunity (Batlle and Massague, 
2019; Kloss et al., 2018; Mariathasan et al., 2018). Thus, tumors employ a number of 
mechanisms to suppress CD8
+




Section 1.1.2 Dendritic Cells in Tumor Immunity 
Anti-tumor T cell responses are most robustly primed by professional antigen 
presenting cells (APCs) known as dendritic cells (DCs). These cells are able to internalize 
dead or dying cells and process internalized proteins into 7-9 amino acid peptides that can 
subsequently be presented to CD8
+
 T cells in the context of MHC-I in a process known as 
“cross-presentation” (Cruz et al., 2017; Gardner and Ruffell, 2016). Additionally, these 
cells express high levels of the costimulatory ligands CD80 and CD86 that are able to 
ligate CD28 and initiate the signaling cascade described above. Because of this capability 
to prime T cell responses, these cells have been identified in a number of studies to be 
crucial in the initiation of anti-tumor immunity (Gardner and Ruffell, 2016). In this context 
T cell priming may happen in the tumor microenvironment, draining lymph nodes, and 
tumor-associated tertiary lymphoid structures (Broz et al., 2014; Joshi et al., 2015; Roberts 
et al., 2016). Subsequently, activated T cells are able to expand and kill tumor cells that 
present a cognate antigen on their surface via MHC-I (Heath et al., 1989). 
Because of this crucial role, much work has been done to characterize populations of DCs 
in the TME. This work has described several major populations thus far: DC1, DC2, DC3, 
and pDC. DC1 are thought to be the major cross-presenting APC in the TME, and are 
crucial for anti-tumor CD8
+
 T cell responses. These cells are rare, and may be 
characterized by expression of the integrin CD103, and are dependent on the transcription 
factor BATF3 for differentiation (Broz et al., 2014; Murphy, 2013). Conversely, DC2 are 
poor activators of CD8
+
 T cell responses, but have been hypothesized to drive CD4
+
 T cell 
responses. These cells are much more prevalent in the TME than DC1, and can be defined 
by the transcription factor IRF4 and expression of the integrin CD11b (Binnewies et al., 
2019; Murphy, 2013). The DC3 subset was recently defined as a migratory population that 
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is hypothesized to traffic from the tumor to local lymph nodes in order to interact with 
circulating immune cells. They may have features of both DC1 and DC2, making it unclear 
if these cells represent a unique lineage or an activation state; regardless, they appear to 
be important for T cell priming in draining lymph nodes (Zilionis et al., 2019). Finally, 
plasmacytoid DCs (pDC) have been observed in many tumors, but their role in anti-tumor 
immunity remains unclear. These cells are well-characterized in the context of viral 
infection to produce high levels of Type I IFN (IFN-I), and as such may represent a source 
of inflammatory signaling in the TME if activated (Musumeci et al., 2019). 
Because of the key role for DCs, factors that drive recruitment (Spranger et al., 2015; 
Spranger et al., 2017), activation (Beatty et al., 2011; Salmon et al., 2016), and function 
(Carreno et al., 2013; Carreno et al., 2015) of DCs (and DC1 in particular) have been of 
intense interest to the field. To this end, chemokines such as CCL7 (Roberts et al., 2016) 
have been implicated in the recruitment of DCs to the TME. Similarly, soluble factors such 
as TGFB (Spranger et al., 2015) have been shown to depress the function of these cells 
when they arrive at the TME, and constitute additional resistance mechanisms employed 
by tumors to limit anti-tumor immunity. 
Despite progress, endogenous signals that drive DC activation in the TME remain 
understudied. In the context of viral or bacterial infection, the recognition of pathogen 
associated molecular patterns (PAMPs) such as LPS, cytosolic DNA, and double stranded 
RNA (dsRNA) has been well characterized to drive activation of these cells and 
upregulation of antigen presentation machinery (Joffre et al., 2009; Kandasamy et al., 
2016; Sprokholt et al., 2017b). In this way, DCs are critical bridges from innate to adaptive 
immunity. Yet how similar “non-self” molecular patterns might be present in the TME has 




Section 1.1.3 ILC1 Cells in Tumor Immunity 
Group 1 innate lymphoid cells (ILC1s) can be split between classically defined 
natural killer (NK) cells and recently defined ILC1 cells by the expression of several surface 
markers (Spits et al., 2016). Regardless of classification, these cells act as major 
producers of IFNG and Perforin/Granzyme in viral and cancerous contexts (Chiossone et 
al., 2018). While functionally similar to T cells, these cells lack antigen-specific receptors 
and instead act on a balance of signaling inputs interpreting stress cues in their local 
environment. Specifically, these cells express activating receptors that recognize stress 
ligands such as MICA/MICB in humans and MULT1 in mice, as well as inhibitory receptors 
that recognize healthy expression of molecules like MHC-I. Stress receptors are generally 
activating (i.e. NKG2D), while receptors that recognize MHC-I tend to be inhibitory (i.e. 
Ly49a, KIR2DL2/3) (Lanier, 2005). In this way healthy cells that express high levels of 
MHC-I fail to activate these cells, while those that downregulate MHC-I or upregulate 
stress molecules are recognized and cleared from the body (Deng et al., 2015; Karre et 
al., 1986; Paczulla et al., 2019). These receptor families are extensive and capable of 
integrating many signaling inputs in a single cell (Cerwenka et al., 2001). By combining 
both activating and inhibitory signals ILC1/NK cells are able to recognize stressed cells by 
ligand expression as well as infected cells seeking to evade CD8
+
 T cell recognition by 
downregulation of MHC-I. This role is particularly well studied in the context of antiviral 




To date, research on the role of these cells in anti-tumor immunity has been restricted 
largely to liquid tumors in which experimental systems have been explicitly designed to 
lack MHC-I expression or express NKG2D ligands (Cerwenka et al., 2001; Deng et al., 
2015; van den Broek et al., 1995). Clinically, this has resulted in a focus on leukemias and 
graft-vs-tumor effects (Boudreau et al., 2017; Mavers and Bertaina, 2018). However, loss 
of MHC-I is an emerging resistance mechanism to immunotherapies focused on the 
activation of CD8
+
 T cells (Rooney et al., 2015; Sade-Feldman et al., 2017; Zaretsky et 
al., 2016). In this context we might expect ILC1/NK cells to play a role in tumor recognition 
and control based on a loss of inhibitory signaling regulated by normal levels of MHC-I. 
Further studies have also revealed the heterogeneity of the NK/ILC1 compartment in the 
TME, and identified TGFB as a key regulator of differentiation (Cortez et al., 2017; Gao et 
al., 2017). Thus, optimal priming of these cells may be a key regulator of anti-tumor 
immunity in tumors with low MHC-I expression. 
 
Section 1.1.4 Macrophages and Monocytes in Tumor Immunity 
Cells that provide suppressive cytokine signals such as TGFB are of intense interest to 
the field, as they impede optimal immune activation. Monocytes are cells of the myeloid 
lineage that circulate with high frequency and give rise to macrophages and MDSCs 
(myeloid-derived suppressor cells) in the TME (Laviron and Boissonnas, 2019). This is 
thought to be analogous to a similar role in wound-healing that is co-opted by tumors as 
an immune-suppressive mechanism (Muliaditan et al., 2018). Indeed, macrophages and 
MDSCs are largely immune-suppressive and are frequently the most prevalent immune 
cell type in the TME. Monocyte recruitment is achieved through enhanced expression of 
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chemoattractants such as CCL2 and CXCL1 by tumor cells followed by differentiation into 
macrophages or MDSCs in the TME (Quail and Joyce, 2013). 
There are multiple mechanisms by which macrophages suppress anti-tumor T and 
ILC1/NK cell responses. The most well-characterized of these is differentiation into an 
“M2” macrophage phenotype. This phenotype is highly prevalent in tumors, and is 
associated with high levels of IL-10 and TGFB production that blunt activation of anti-
tumor effector cells. In turn, M2 macrophage differentiation itself is thought to be regulated 
by IL10 and TGFB produced by tumor cells and pre-existing macrophages present in the 
local microenvironment (Batlle and Massague, 2019). This drives a forward-feeding loop 
that enforces a suppressive, non-inflammatory microenvironment within the tumor. A 
second major immune-suppressive mechanism deployed by macrophages in the TME is 
the high expression of PDL1 (PD1 ligand) (Benci et al., 2016). This ligates PD1 expressed 
on both T cells and ILC1/NK cells, inhibiting the full activation potential of these cells.  This 
acts as a second pool of PDL1 on top of that expressed on tumor cells (Pesce et al., 2019; 
Sharpe and Pauken, 2018; Sun et al., 2018). Multiple studies have demonstrated that 
depletion, inhibition, or repolarization (Dammeijer et al., 2017; Hoves et al., 2018; 
Pyonteck et al., 2013) of macrophage function in the TME is an effective way to enhance 
anti-tumor immune responses, underscoring the crucial pro-tumor role that these cells play 
in regulating anti-tumor immunity. 
MDSCs play a similar role to macrophages in the TME, albeit through slightly different 
reported mechanisms. These cells are well characterized suppressors of T cell function; 
unlike traditional M2 macrophages, MDSCs are thought exert pro-tumor function mainly 
through inhibitory soluble factors such as IDO, iNOS, and ARG1/2 (Gabrilovich, 2017). 
Thus, they enhance the immune-suppressive microenvironment that fosters malignant 
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tumor growth through orthogonal mechanisms. Similar to macrophages, many studies 
have characterized approaches that limit the function or prevalence of these cells in the 
TME and improve anti-tumor immunity (Anani and Shurin, 2017). Unfortunately, these 
approaches have yet to yield robust clinical benefits, demonstrating the need for novel 
approaches to modulate the emergence of these cells in the TME. 
 
Section 1.1.5 CD4+ T cells in Tumor Immunity 
CD4
+
 T cells will not be covered in depth in this thesis but are important contributors to the 
tumor-immune microenvironment. CD4
+
 T cells come in a variety of subtypes, but most 
well-characterized in the TME are CD4
+
 T regulatory cells (Tregs). These cells are thought 
to differentiate in response to TGFB in the TME and also to traffic to the TME in response 
to inflammation (Tanaka and Sakaguchi, 2017). They function to inhibit CD8
+
 T and NK 
cell responses through a variety of proposed mechanisms including negative 
costimulatory ligation, TGFB secretion, and CD80/86 or IL-2 sequestration (Josefowicz et 
al., 2012). All of these mechanisms result in sub-optimal T cell priming and favor tumor 
growth. Other CD4
+
 T cell subtypes such as Th1, Th2, and Th17 have been shown to 
influence the tumor immune microenvironment in various manners (Karin and Wildbaum, 
2015), but will not be covered here. 
 
Section 1.2 – Inhibitory Checkpoint Blockade 
 
As mentioned above, T cells integrate costimulatory signals during priming and target 
recognition. These costimulatory receptors can be activating or inhibitory; the activating 
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CD28 signaling cascade was described briefly above, in which ligation of CD28 by CD80 
or CD86 initiates the phosphorylation of SLP76, which eventually converges on NFkB 
signaling (Smith-Garvin et al., 2009). This process is antagonized by two key negative 
costimulatory receptors also expressed by T cells: PD1 and CTLA4. This section will 
describe the biology of inhibitory costimulatory molecules and clinical progress in the 
development of blocking antibodies for these pathways. 
 
Section 1.2.1 PD1 and CTLA4 in T cell exhaustion 
In response to acute viral and bacterial infections, T cells undergo rapid differentiation 
from a naïve cell type to a mature effector cell in order to clear the offending pathogen. 
This is followed by a contraction phase and the establishment of immune memory by a 
small pool of memory T cells (Kaech et al., 2002). The expansion of effector cells is 
required for clearance of many pathogens, and is a hallmark of productive immune 
responses. These cells are characterized by high levels of inflammatory cytokine 
production like IFNG and TNF, as well as robust killing capacity through expression of lytic 
molecules like Granzyme B (Kaech et al., 2002). This state is generally thought to be the 
product of effective integration of Signals 1, 2, and 3 described above and is associated 
with a wide variety of productive immune responses (Kaech and Cui, 2012). For this 
reason, some persistent or chronic infections and cancers employ mechanisms to limit 
this productive T cell expansion and instead drive a more dysfunctional T cell state termed 
T cell exhaustion (Wherry and Kurachi, 2015). 
T cell exhaustion is a widely studied phenomenon that may be driven by chronic antigen 
stimulation, improper co-stimulation, suppressive cytokine exposure, or a combination of 
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these factors. This dysfunctional state is characterized by lower production of 
inflammatory cytokines like IFNG and TNF, as well as a diminished ability to kill target 
cells (Wherry and Kurachi, 2015). Extensive studies have demonstrated that this cell state 
is regulated by a core transcriptional program orchestrated by the transcription factor 
TOX1 (Alfei et al., 2019; Khan et al., 2019; Scott et al., 2019), which includes decreased 
chromatin accessibility of effector T cell genes and increased accessibility of inhibitory 
receptors such as PD1 and others (Pauken et al., 2016). This state is hypothesized to 
arise in viral infections as an evolutionary adaptation to limit immune pathology in chronic 
infections (Barber et al., 2006); however, many tumors impose this program to limit T cell 
function and favor tumor growth (Sun et al., 2018). For example, tumor cells frequently 
express high levels of PDL1 in order to limit T cell activation through the ligation of PD1 
on T cells. Similarly, the secretion of the suppressive cytokine TGFB can act directly on 
cytotoxic T cells, while also recruiting regulatory T cells that utilize the inhibitory co-
receptor CTLA4 to prevent optimal T cell priming as discussed above. Examples of these 
negative costimulatory regulators employed by tumor cells abound and will be discussed 
in this section. 
PD1 (Programmed Death receptor 1) acts through the intracellular phosphatase SHP2 
upon ligation with its cognate receptor PDL1. SHP2 dephosphorylates key components of 
the TCR signaling pathway such as ZAP70 and PI3K, effectively stopping TCR signaling 
and blunting activation of the T cell (Arasanz et al., 2017). This is thought to promote 
immune/pathogen stalemate in the context of infectious disease in order to limit 
immunopathology (Barber et al., 2006; Wherry and Kurachi, 2015); but in the context of 
the TME, it effectively renders T cells unable to kill tumor cells and promotes tumor growth 
(Benci et al., 2016; Sun et al., 2018). Thus, antibodies that block this PD1/PDL1 interaction 
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should effectively release this T cell inhibition and enhance T cell killing in the tumor. 
Indeed, this result has been achieved through a number of now clinically available 
antibodies (Mahoney et al., 2015), several of which have demonstrated impressive clinical 
efficacy. 
Alternatively, CTLA4 acts by sequestering CD80 and CD86 from CD28 ligation through a 
higher affinity interaction. This effectively deprives the T cell of positive costimulatory 
signaling and achieves a similar result to PD1 ligation by limiting the level of TCR pathway 
activation. This leads to poor T cell priming and enforces the T cell exhaustion program 
(Esensten et al., 2016). While the major PD1/PDL1 interaction is thought to occur mainly 
between T cells and tumor cells, this CTLA4/CD80-86 interaction is thought to happen 
mostly at the level of DC/T cell priming and Treg/T cell intratumoral interactions (Dyck and 
Mills, 2017). In this way, tumors limit the priming of cytotoxic T cells at multiple checkpoints 
in the activation process and impose a state of T cell exhaustion that favors tumor growth. 
 
Section 1.2.3 Clinical Successes Utilizing Checkpoint Inhibitors 
Treatment of cancer with antibodies that block these inhibitory checkpoint molecules has 
been termed inhibitory checkpoint blockade (ICB), and has fundamentally changed the 
treatment of some advanced cancers. The first major clinical results demonstrating the 
efficacy of this approach were published roughly 10 years ago now, with the major 
conclusion that remissions achieved after treatment with these ICB therapies were 
extremely durable (Wolchok et al., 2013). This is reminiscent of immunological memory 
observed in murine experiments (Leach et al., 1996), and represents a level of tumor 
control rarely achieved by small-molecule therapies. 
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Unfortunately, the most dramatic responses have been limited to specific subsets of 
cancers. Notably, responses in melanoma and NSCLC appear particularly robust following 
ICB therapy (Gandhi et al., 2018; Wolchok et al., 2013). This may be explained by high 
levels of previous immune infiltration (Hellmann et al., 2018), as well as high levels of 
tumor mutational burden (Alexandrov et al., 2013). However, even tumor types with 
relatively high levels of mutational burden, such as NSCLC, respond to therapy in a 
durable fashion only ~20% of the time (Gandhi et al., 2018). This may be attributed to 
several factors; first, many tumors simply exist as immune deserts. In this case, no T cells 
are present to become activated following ICB therapy, and therefore the therapy is 
ineffective (Teng et al., 2015). A similar scenario has also been described in which T cells 
are limited to the margins of the tumor; these tumors are known as “T cell excluded” 
(Mariathasan et al., 2018). In other cases, adaptive resistance mechanisms such as MHC-
I loss, TGFB suppression, or metabolic rewiring may prevent T cells from becoming 
properly activated even in the context of enhanced priming facilitated by ICB (Bengsch et 
al., 2016; Kloss et al., 2018; Sade-Feldman et al., 2017). Finally, a tumor may have no 
recognizable mutant T cell neoantigens; in this case there is simply nothing for the T cells 
to recognize and ICB is priming T cells that have no relevant target (Alexandrov et al., 
2013). For these reasons, more innovation is required to expand the clinical benefit being 
realized from the basic understanding of T cell biology and tumor-immune interactions. 
 
Section 1.2.3 Additional Negative Costimulatory Receptors 
Since the discovery of PD1 and CTLA4, many additional T cell inhibitory costimulatory 
receptors have been identified. Tim3, Lag3, and TIGIT, among others have been 
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demonstrated to be of particular relevance to enforcing the T cell exhaustion phenotype. 
These receptors bind various ligands associated with T cell/APC interactions, and 
generally converge on intracellular ITIM motifs to suppress TCR pathway signaling 
through phosphatase activation. While these receptors will not be covered in detail in this 
thesis, significant work has been done to elucidate the importance of these receptors in 
the context of anti-tumor immunity. Despite the insight gained, clinical blockade strategies 
targeting these receptors have shown significantly less efficacy than anti-PD1 and anti-
CTLA4 strategies. This may imply that PD1 and CTLA4 act as master regulators of T cell 
activation in the TME, and that there is additional underlying biology that we have yet to 
understand (Chen and Flies, 2013). 
 
Section 1.3 – Interferon signaling in cancer 
 
Both IFN-gamma (IFNG) and Type I IFN (IFN-I) are known to have critical roles in anti-
tumor immunity. IFN enhances immune function by inducing expression of MHC-I (Dighe 
et al., 1994), which is constitutively expressed on many tissues, and by enabling dendritic 
cells to cross-prime T cells (Diamond et al., 2011; Fuertes et al., 2011). In this way, IFNs 
are important in the early phase of antigen recognition and are crucial to the interaction 
between adaptive and innate immunity. Accordingly, loss-of-function mutations and 
genomic alterations in the IFN/JAK signaling pathway have been associated with clinical 
ICB resistance and/or relapse (Gao et al., 2016; Shin et al., 2017; Zaretsky et al., 2016), 
and unbiased genetic screens have identified this same pathway as being important for 
immunotherapy response in certain mouse models (Manguso et al., 2017; Mezzadra et 
al., 2017). In contrast, some patients with mutations in the IFN pathway still respond to 
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ICB (Hellmann et al., 2018; Sade-Feldman et al., 2017) or have high serum levels of IFNG 
that associates with ICB progression (Huang et al., 2017). These paradoxical observations 
may represent immunosuppressive properties of the IFN pathway. 
 
Section 1.3.1 IFNG in the Tumor Microenvironment 
IFNG is an immune-stimulatory cytokine that is produced at high levels by activated T and 
NK cells during viral and bacterial infections. This cytokine signals to a variety of other 
immune and non-immune cell types through a dedicated IFNG-receptor (IFNGR), which 
is made up of a heterodimer consisting of IFNGR1 and IFNGR2. Upon ligation of IFNG, a 
complex of 2 IFNGR heterodimers is formed, creating an active signaling complex of two 
heterodimer receptors and two IFNG molecules (Mendoza et al., 2019). This active 
complex phosphorylates the transcription factor STAT1 via JAK1/JAK2 kinases, inducing 
STAT1 dimer formation and nuclear translocation. This signaling converges on a well-
studied set of genes termed “interferon stimulated genes” (ISGs), that are critical to anti-
viral and bacterial immunity (Castro et al., 2018). 
Since the discovery that T and NK cells are also able to recognize tumor cells (Asjo et al., 
1977; Schick and Berke, 1977), there has been much interest about how IFNG affects the 
TME. Several studies have demonstrated the importance of IFNG in DCs that cross-prime 
anti-tumor CD8
+
 T cells (Diamond et al., 2011; Frasca et al., 2008), as well as a crucial 
role for initiating and enforcing inflammatory gene programs in macrophages (Ivashkiv, 
2018; Kaneda et al., 2016). In DCs, IFNG is crucial for activation of antigen-processing 
machinery that facilitates cross-presentation to CD8
+
 T cells (Matsuo et al., 2004). This 
process is particularly crucial in anti-tumor contexts, as dead or dying tumor cells must be 
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internalized and processed by DCs in order to prime CD8
+
 T cells to recognize tumor 
neoantigens (Roberts et al., 2016). Moreover, costimulatory molecules CD80 and CD86 
are well-defined ISGs that enhance T cell priming when upregulated in DCs (Castro et al., 
2018). In macrophages, IFNG enforces an inflammatory gene program and chromatin 
state that is actively repressed by intracellular PI3K in the TME (Kaneda et al., 2016). 
Thus, IFNG may represent a crucial regulator of macrophage polarization in the TME, and 
a key determinant of immune activation. This suggests an important role for IFNG in 
activating anti-tumor gene programs in the myeloid compartment. Interestingly, recent 
evidence has suggested an opposing role in T cells in which high levels of IFNG signaling 
may lead to activation-induced cell death (Pai et al., 2019). This may represent another 
evolutionary mechanism for limiting immune pathology during pathogenic infections, but 
could limit T cell expansion in tumors. 
Further supporting the pleiotropic role for this cytokine in the TME, conflicting reports have 
described both positive and negative roles for IFNG signaling in tumor cells. As mentioned 
above, IFNG is a strong stimulus for the upregulation of MHC-I, which is crucial for CD8
+
 
T cell responses. However, signaling also drives expression of inhibitory ligands such as 
PDL1 and Galectin-9, among others, on the surface of cancer cells (Benci et al., 2016). 
This enforces T cell dysfunction and favors tumor growth. Further, high MHC-I expression 
limits the activation of NK cells in the tumor, which favors tumor growth in contexts of low 
neoantigen prevalence. These opposing outcomes are seemingly contradictory, and the 
outcome of tumor/immune interactions in this setting are likely context dependent. 
 
Section 1.3.2 Type I IFN in the TME 
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Unlike IFNG, IFN-I is mainly a product of innate immunity. During viral infections, it is 
produced at high levels by macrophages, DCs, and epithelial cells that recognize infection 
and seek to alert neighboring immune cells. This family of cytokines includes IFN-beta 
(IFNB), and multiple subtypes of IFN-alpha (IFNA), both of which signal through a shared 
IFN-I receptor (IFNAR). IFNAR signaling leads to the formation of heterodimers of 
phosphorylated STAT1 and STAT2 that translocate to the nucleus and upregulate ISGs 
that are overlapping, but not identical to those triggered by IFNG signaling (Lee and 
Ashkar, 2018). Interestingly, IFNA was proposed and tested as one of the first 
recombinant protein therapeutics for induction of anti-tumor immunity (Borden, 2019). In 
recent years our understanding of the pleiotropic role of this pathway in the TME has 
improved and suggests more targeted therapeutic approaches may improve this 
paradigm. 
IFN-I target ISGs play a variety of roles depending on cell type. For example, in 
macrophages IFN-I is strongly associated with M1 macrophage polarization (Park et al., 
2017; Snell et al., 2017), and drives differentiation of monocytes to an inflammatory 
phenotype instead of a pro-tumor MDSC phenotype (Dangi et al., 2018; Santini et al., 
2000). Similar to IFNG, IFN-I drives upregulation of costimulatory molecules and antigen 
presentation machinery in DCs that facilitate T cell activation. During this priming process, 
IFN-I in the local microenvironment acts as an important Signal 3 molecule, priming 
effector CD8
+
 T cell responses and Th1 CD4
+
 T cell responses (Longhi et al., 2009; Wiesel 
et al., 2012). In mice that lack IFNAR, antiviral (Kolumam et al., 2005) and anti-tumor 
(Diamond et al., 2011) T cell responses are severely curtailed, leading to ineffective 
clearance and enhanced morbidity. These IFN-I primed T cells are characterized by an 
upregulation of survival programs that include BCL-XL, as well as induction of TBET, a 
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master regulator of T cell differentiation. Accordingly, T cells that lack IFNAR are unable 
to differentiate into short-lived effector cells and control viral infections (Marrack et al., 
1999; Wiesel et al., 2012). Similar studies have not yet been carried out in tumors, but 
consistencies between anti-viral and anti-tumor T cell studies would suggest a similar role 
for IFN-I in anti-tumor T cell priming.  
Consistent with the pleiotropic role of many cytokines in the TME, IFN-I signaling in tumor 
cells has been additionally correlated with resistance to therapy. This was first described 
as a broad resistance signature to chemotherapy, radiation, or a combination of the two 
(Weichselbaum et al., 2008). However, in recent years a more nuanced understanding 
has been reached in which some core ISGs predict resistance to therapy (Boelens et al., 
2014; Nabet et al., 2017), while others that are more critical to immune activation predict 
response to therapy (Manguso et al., 2017; Patel et al., 2017). This is unsurprising given 
the nature of IFN-I target genes; for example, BCL-XL upregulation in tumor cells is likely 
to favor tumor growth and survival (Boise et al., 1993; Kumar et al., 1996), while 
upregulation of MHC-I and antigen processing will favor immune recognition, cell death, 
and responsiveness to therapy (Patel et al., 2017). Thus, a central hypothesis of this thesis 
is that the relative cellular localization of inflammatory signaling is a key determinant to the 
activation of these pathways in the TME. Since the source of these signaling pathways is 
generally thought to be the recognition of viral or bacterial infection, how the production of 
IFN-I is initiated in the TME is of significant interest. 
 




Pathogen associated molecular patterns (PAMPS) have (unsurprisingly) been most well 
described in the context of pathogenic infections. Generally, this term refers to molecular 
patterns that are “foreign” to the eukaryotic immune system. For example, the detection 
of double-stranded or structured RNA/DNA in the cytoplasm by pattern recognition 
receptors (PRRs) alerts the host to viral infection. Similarly, detection of bacterial cell wall 
components activates anti-bacterial immunity and aid in the clearance of infections 
(Kawasaki and Kawai, 2014; Schlee and Hartmann, 2016). However, in recent years a 
budding literature has emerged around a role for pattern recognition receptors in anti-
tumor immunity and tumor-associated inflammation (Zitvogel et al., 2015). This implies 
that tumors are producing pathogen-like molecules in some contexts and suggests a role 
for innate immune pathways in the discrimination of self vs non-self in anti-tumor immunity. 
 
Section 1.4.1 STING signaling in the TME 
STING is a cytoplasmic DNA sensor that works in concert with its partner protein cGAS. 
Upon recognition of cytoplasmic DNA cGAS becomes activated and produces the 
messenger molecule cyclic guanine adenosine monophosphate (cGAMP). cGAMP is then 
recognized by STING, which initiates a signaling cascade that converges on 
phosphorylation of the IRF3 transcription factor and a core ISG gene program (Chen et 
al., 2016). This process is normally associated with recognition of DNA viruses, but in 
recent years it has become appreciated that genome instability in tumor cells allows for 
release of DNA into the cytoplasm as free-floating DNA or microsatellites (Barber, 2015; 
Li and Chen, 2018). In this way, STING may act as genomic stress sensor, similar to the 
RNA sensor PKR, that alerts surrounding cells to decreased cellular fitness. 
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In contrast to the paradigm described above for IFN-I and IFNG, DNA damage and 
activation of the STING pathway seem uniformly pro-immunogenic and enhance response 
to ICB. In general, chromosomal instability or microsatellite formation leads to immune 
activation (Harding et al., 2017) or senescence (Dou et al., 2017) that synergize with 
checkpoint blockade strategies. On this basis, several interventional approaches have 
been investigated to trigger STING activation in the TME. These may involve the use of 
ionizing radiation that causes double-stranded DNA breaks (Deng et al., 2014), or injection 
of STING agonist molecules directly in the TME (Ager et al., 2017; Corrales et al., 2015; 
Ramanjulu et al., 2018). However, it is worth noting that DNA damage is associated with 
increased rates of mutation which can confer resistance to many therapeutic modalities 
(Vasan et al., 2019). 
STING agonists seek to trigger the STING pathway in immune cells present in the TME, 
leading to enhanced anti-tumor immunity. Encouragingly, strategies such as radiation 
combined with ICB have demonstrated some clinical efficacy (Twyman-Saint Victor et al., 
2015), although it is difficult in this setting to attribute that benefit to any one specific 
molecule or pathway. The outlook is less positive for strategies utilizing direct STING 
agonist molecules, usually in the form synthetic di-nucleotides. Thus far, systemic delivery 
of these molecules either alone or in liposome-encapsulated formulations has not been 
able to achieve relative concentrations high enough to generate robust clinical anti-tumor 
responses (Riley et al., 2019). This is associated with general inflammatory toxicity from 
systemic delivery (Hu et al., 2019), as well as localization of liposomes to liver and kidneys 
instead of sites of disease (Sercombe et al., 2015). Alternatively, direct injection at tumor 
sites has shown robust responses in preclinical models (Corrales et al., 2015), but is not 
necessarily appropriate for patients with difficult to reach or multiple metastatic sites. Thus, 
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deeper understanding of PRR biology in the TME and novel targeted approaches are 
needed to leverage these pathways for improving outcomes following ICB therapy. 
 
Section 1.4.2 dsRNA signaling in the TME 
Like cytoplasmic DNA, double-stranded or highly structured RNA is a common viral 
nucleic acid motif. In recent years such RNAs have also emerged as a potent inducer of 
ISGs in both tumor and immune cells in the TME. This RNA motif is detected in the 
cytoplasm by the PRRs MDA5 and RIG-I, and in endosomes by TLR3 (Schlee and 
Hartmann, 2016). In the cytoplasm, MDA5 is thought to recognize foreign RNAs through 
a structural mechanism that favors longer RNAs, while RIG-I activation is triggered by 
shorter RNAs that contain a 5’ tri-phosphate moiety that is less dependent on structure 
(Brisse and Ly, 2019). This 5’ tri-phosphate serves as distinguishing feature of foreign 
RNA, as eukaryotic mRNA transcripts are transcribed by RNA Polymerase-II which 
cleaves this 5’ tri-phosphate and leaves instead a 5’ -OH. Additionally, the majority of non-
messenger RNA in eukaryotic cells contains a 5’-monophosphate. Viral polymerases are 
not able to create these motifs, and so even short and non-structured viral RNAs may be 
recognized by eukaryotic hosts (Phatnani and Greenleaf, 2006; Vignuzzi and Lopez, 
2019). Both RIG-I and MDA5 signal through the adaptor protein MAVS that acts as a 
signaling platform located on the mitochondria and translates this recognition of foreign 
RNA into phosphorylation and activation of transcription factors IRF3 and IRF7. This 
results in the upregulation of an antiviral ISG signature including robust production of IFN-
I (Schlee and Hartmann, 2016). 
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Frequently the RNAs that are recognized by these PRRs in tumors are endogenous 
retroviral elements that have been incorporated into the human genome, but are 
repressed in the steady state. They may be de-repressed by epigenetic changes 
associated with cancerous transformation (Sheng et al., 2018), or through therapeutic 
interventions such as DNMT inhibitors (Chiappinelli et al., 2015), and radiation (Lee et al., 
2020). Regardless of how they become derepressed, the recognition of these stimulatory 
RNAs generates an inflammatory IFN-I genomic signature in a variety of experimental 
systems. And again, reports differ on the effect of these elements in the TME. This 
underscores that further study is required to understand the determinants of survival 
outcomes, despite many of these inflammatory processes converging on similar gene 
programs (Boelens et al., 2014; Sheng et al., 2018). 
To this point, most studies have focused on cancer or immune-specific effects of such 
RNAs, while ignoring potential competition or interplay between these two cellular 
compartments. For example, several papers have demonstrated that intratumoral 
administration of dsRNA ligand Poly I:C improves anti-tumor immunity and response to 
ICB both in mice and human (Hammerich et al., 2019; Salmon et al., 2016). These papers 
largely ignore effects on tumor cell signaling, while papers that have characterized tumor 
recognition of endogenous dsRNA elements focus mainly on tumor cell-intrinsic effects of 
PRR activation (Boelens et al., 2014; Nabet et al., 2017). In this case, pro-tumor effects 
of intratumoral inflammation and IFN-I signatures are highlighted. Given that both 
instances give rise to robust phenotypes, more work is needed to understand the 
interaction between these populations. 
Of particular interest is the endogenous non-coding RNA RN7SL1 (7SL). This RNA is 
derived from an ancient retroviral element and is conserved from mammals to bacteria 
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(Denks et al., 2014). It has significant secondary structure and functions as a scaffold for 
the signal recognition particle (SRP) complex, which facilitates translation of 
transmembrane proteins (Halic and Beckmann, 2005). Transcription of this RNA is 
controlled by an RNA Pol-III promoter, and unlike mRNA produced by RNA Pol-II, the 5’ 
tri-phosphate of the RNA is not processed (Phatnani and Greenleaf, 2006). Additionally, 
this promoter is sensitive to MYC and so is intrinsically linked to cellular growth signals 
(Campbell and White, 2014). In homeostatic conditions, the SRP complex decorates the 
RNA and shields 7SL from recognition by the cytoplasmic dsRNA sensors described 
above. However, in some cancerous contexts with high levels of Notch and MYC 
signaling, the stoichiometry of 7SL RNA and SRP complex proteins can be dysregulated 
in such a way that that 7SL RNA is over-produced and will not bound by SRP proteins. In 
this case, unshielded 7SL RNA becomes available for recognition by PRRs. This drives a 
tumor-cell intrinsic ISG program that enhances tumor growth and resistance to ICB 
therapy (Nabet et al., 2017). The effect that such an RNA might have on immune cells in 
the TME would be of significant interest to the field and could elucidate context-specific 
effects for these inflammatory stimuli. 
 
Section 1.5 – Extracellular RNA Transfer and Communication 
 
While soluble cytokines such as IFN-I often act as the extracellular messengers that 
communicate PRR activation to neighboring cells, PAMPs themselves may also be 
transferred between cells via extracellular vesicles. Extracellular vesicles (EVs) are a class 
of sub-cellular lipid vesicles that are characterized by a lipid membrane and are sub-
classified by size into categories including microvesicles, exosomes, and large EVs, 
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among others. EVs are derived from the endosomes or plasma membranes of living cells, 
maintain surface expression of some surface receptors, and are loaded with biological 
cargo including nucleic acids and proteins, but are unable to independently replicate. In 
general, EVs favor smaller cargo including miRNAs, lncRNAs, small peptides, and 
secondary messengers, raising an intriguing possibility that these vesicles may serve as 
important cell-to-cell communication vehicles (Raposo and Stoorvogel, 2013). 
 
Section 1.5.1 Tumor Extracellular Vesicle Communication 
Tumors are well-known to utilize EVs for the purpose of altering extracellular processes, 
first characterized in the context of miRNAs. In many cases, tumors export miRNAs in 
complex with DICER/AGO processing machinery; this has been reported to promote EMT 
mesenchymal differentiation (Whiteside, 2018), enhanced fibroblast differentiation (Yang 
et al., 2017), and immune suppression (Whiteside, 2016), among other processes. 
Subsequent studies have confirmed that tumor-derived miRNAs can limit DC (Yu et al., 
2007) and T cell (Curtale et al., 2010) activation, further favoring tumor growth. Additional 
evidence for EV-mediated transfer of protein cargo was demonstrated by observing Cre-
recombinase mediated genetic deletion in mixed populations such that no cell expressed 
all necessary components internally (Pucci et al., 2016). This evidence is particularly 
compelling because it necessitated the transfer of EV cargo from the cell surface into the 
nucleus to affect the genome of the acceptor cell. This opens the possibility that tumor 
cells may export malignant proteins that are produced in abundance like MYC or RAS to 
neighboring cells, further enhancing their proliferative potential. This a powerful tool for 
cancer cells to export proteins and complexes that modulate transcriptional programs and 
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phenotypes of neighboring cells in the TME to their advantage. Indeed, many groups have 
suggested that exosomal secretion is required for metastatic niche preparation and drives 
metastatic potential of tumors (Becker et al., 2016). 
 Conversely, tumor-derived EVs may also contain immunogenic molecules due to the 
structured nature of many lncRNAs and nucleotide based secondary messengers. For 
example, cGAMP is often transferred between cells via gap junction (Ablasser et al., 2013; 
Schadt et al., 2019) and EVs (Bridgeman et al., 2015; Gentili et al., 2015) in order to 
propagate recognition of DNA viruses by activating STING in neighboring cells. Indeed, 
DNA microsatellites in tumor cells were able to initiate cGAS-mediated production of 
cGAMP which enhanced anti-tumor immunity (Harding et al., 2017). Crucially in this case, 
host STING was required for anti-tumor immunity, implying that cGAMP was being 
transferred from tumor cells to neighboring immune cells in the TME in some way. 
Similarly, RN7SL1 was identified as an inflammatory stimulus by studying EV RNA that 
was transferred from fibroblasts to tumor cells (Nabet et al., 2017). This highlights the 
complex nature of EV cargo and multitude of pathways that it may influence in acceptor 
cells. 
Finally, many tumor-derived EVs retain surface molecules such as PDL1 and TGFB (Chen 
et al., 2018; Shelke et al., 2019). Similar to tumor cell surface ligands, these suppress anti-
tumor immunity, such that even with immunogenic cargo the uptake of these EVs may 
represent an immunosuppressive event. The confluence of these pathways are a 
microcosm for the TME as a whole, and point to a need for understanding of the factors 




Section 1.5.2 Extracellular Vesicle Sorting 
As EVs bud from the cellular membrane, it is clear that cargo is loaded into these bodies. 
However, whether this is a passive or active process remains a subject of significant 
debate. Given that many EV-enriched surface receptors contain intracellular domains, it 
is an attractive possibility that these proteins direct cargo sorting and enrich for specific 
molecules or motifs, similar to clathrin-coated vesicles. Indeed, the receptor ALIX is 
thought to sort some protein cargo specifically into EVs in a ubiquitin-dependent manner 
(Bebelman et al., 2018). Similarly, it has been hypothesized that integrin inclusion on the 
surface of EVs targets vesicles to specific acceptor cells based on reciprocal integrin 
expression. This is supported by the specification of tumor metastases to specific 
anatomic sites given tumor-EV integrin expression independent of tumor type (Hoshino et 
al., 2015). 
A competing school of thought places more emphasis on passive localization than active 
sorting in these processes. In this case, cargo that is nearest the plasma or endosomal 
membrane as EVs are incorporated is included in the vesicle. Thus, size and frequency 
of a given molecule are the key determinants of EV inclusion. This hypothesis can be 
supported by the frequency of common miRNAs and ncRNAs found in EVs, as well as the 
amount of small protein cargo found in these vesicles as compared to larger molecules 
(i.e. cGAMP vs Cre-recombinase) (Abels and Breakefield, 2016). Similarly in this view, 
acceptor cells are specified more by proximity to secretor cells than specific EV/cell 
interactions. This may be supported the importance of tumor/stroma exosomal 
communication, as these cells frequently reside in tight proximity within the TME (Yang et 
al., 2017). Importantly, these possibilities are not mutually exclusive, and likely both play 




Section 1.6 – CAR-T cell biology 
 
Chimeric antigen receptor (CAR) T cells are engineered ex vivo to recognize and kill tumor 
cells. This is achieved through viral transduction of T cells in order to express a CAR 
molecule that contains two major subunits.  The first is a single chain variable fragment of 
an antibody (scFv) that allows for recognition of tumor cells; this is connected to 
intracellular signaling domains derived from either the 41BB or CD28 costimulatory 
proteins along with the intracellular CD3-zeta chain. This construct as a whole translates 
binding of the scFv to a target antigen into the TCR signaling cascade described in detail 
above, and facilitates killing of the target cell by the engineered T cell (Lim and June, 
2017). This section will outline CAR-T biology and current clinical approaches utilizing this 
novel therapeutic modality. 
 
Section 1.6.1 Current scFv Targets 
scFv recognition and binding of a target antigen is the functional equivalent of TCR/MHC 
interaction in natural T cell target recognition. However, the use of an antibody domain in 
this case allows the CAR-T cell to target stable proteins on the surface of a target cell 
instead of peptide/MHC complexes. The affinity of this scFv/target binding event has 
important implications for CAR-T cell killing. CAR molecules with high affinity kill target 
cells in a more robust fashion (Richman et al., 2018), although this has also been shown 
to result in decreased cellular persistence (D'Angelo et al., 2018). The overall avidity of 
the scFv/target interaction is also related to the copy number of the target antigen, and is 
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an important determinant for the feasibility of targeting a given antigen (Ramakrishna et 
al., 2019). Thus, there must be a balance between expression level and scFv avidity in 
order to achieve optimal CAR-T cell activation. In general, highly expressed proteins have 
been the most popular CAR targets to date, but improved development of scFv and 
camelid nanobody binding domains may change this paradigm moving forward (Jackson 
et al., 2016; Xie et al., 2019). In total, scFv selection must be based on actionable target 
antigen density that is paired with scFv affinity high enough to trigger cytolysis, but low 
enough so as to not drive exhaustion and poor persistence. 
The first and most clinically developed CAR-T target is the B cell lineage protein CD19. 
Anti-CD19 CAR-T cells have been in clinical testing for nearly a decade and have achieved 
ongoing complete response (CR) rates as high as 50% in refractory B-ALL (B cell acute 
lymphoblastic leukemia) (Maude et al., 2018). This is a remarkable achievement in a 
previously devastating disease and has sparked trials in additional indications such as B-
CLL, Non-Hodgkin Lymphoma, DLBCL, and AML. Accordingly, this has sparked the 
development of other blood-focused targets such as CD20, CD22, and CD33 which have 
showed similar levels of pre-clinical efficacy and are currently undergoing clinical testing 
(MacKay et al., 2020). 
There is considerable interest in expanding this treatment paradigm to solid tumors that 
comprise the majority of cancer incidence throughout the world. Targets for common solid 
tumors include PSMA (prostate-specific membrane antigen) in refractory prostate cancer 
(Zhong et al., 2010), HER2 in breast cancer (Ahmed et al., 2007), GD2 in glioblastoma 
(Pule et al., 2008), and mesothelin in lung and pancreatic cancers (Carpenito et al., 2009). 
While extensive pre-clinical research has suggested that such targets may provide viable 
strategies for targeting these cancers, convincing clinical data has not yet emerged to 
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support this idea. Alternatively, strategies have been developed that focus on cancer-
specific mutations instead of wild-type proteins. These include unique glycosylation 
isoforms (Posey et al., 2016), and receptors (EGFRvIII) (Morgan et al., 2012). Again, 
preclinical results in this case are promising but clinical data are not yet available. 
While ICB therapies have shown significantly more clinical efficacy in solid tumors than 
CAR-T cells thus far, CAR-T therapy possesses a crucial advantage that can be leveraged 
in the majority of cancer incidences. While endogenous T cells rely on chemokine cues 
and antigen processing of mutated proteins to enter and kill tumors (Fu and Jiang, 2018), 
CAR-T cells will enter and expand in previously un-infiltrated tumors on the basis of 
engineered target recognition (Posey et al., 2016). In this way, CAR-T cells may have the 
capacity to fundamentally alter the tumor microenvironment in a way that ICB therapies 
are not able to. Beyond this, the localized production of stimulatory cues and/or 
chemotactic molecules within the TME is likely to generate higher effective concentrations 
of relevant molecules than would be tolerable via systemic delivery (Sercombe et al., 
2015). In this way, an engineered T cell might act as a signaling platform with the potential 
to fundamentally restructure the TME through delivery of beneficial cues that are specified 
by the engineer. Thus, one could envision many approaches that leverage underlying 
biology to improve the efficacy of both therapies in combination. 
 
Section 1.6.2 Relevance of Costimulatory Domain  
After physically binding an antigen target through the scFv, CAR-T cells must become 
activated to proliferate and kill target cells. In non-engineered T cells this is accomplished 
through a cascade revolving around the intracellular ITAM domains of the CD3 proteins 
30 
 
and relevant costimulatory Signal 2 proteins discussed in Section 1.1 and 1.2. This is 
mimicked in CAR-T cells through the addition of the ITAM domains of either 41BB or CD28 
along with CD3-zeta. By connecting these intracellular domains in a single chimeric 
protein to the receptor-target synapse formed at the cell surface between scFv and target 
antigen, CAR-T cells are able to effectively mimic the naturally occurring antigen-
recognition process hardwired into T cells during development (June et al., 2018). 
Important differences have been identified between the T cell activation programs that are 
driven by differential use of the CD28 or 41BB intracellular costimulatory domain, despite 
superficially similar cellular functions. Notably, 41BBz CAR-T cells persist more robustly 
than CD28z counterparts (Kawalekar et al., 2016)  and control tumors more effectively in 
some circumstances (Long et al., 2015). In contrast, CD28z-based CAR-T cells kill target 
cells more quickly and produce higher levels of inflammatory cytokines (Zhao et al., 2015). 
This has been associated with higher levels of cytokine release syndrome in the clinical 
setting (Davila et al., 2014) along with higher rates of fatal neurological complications 
(2018). However, this may point to a paradigm in which utilization of different intracellular 
domains can effectively tailor T cell function to individual tumor characteristics on a 
patient-by-patient basis. This is supported by research on additional costimulatory 
domains such as ICOS (Guedan et al., 2018) and MyD88 (Mata et al., 2017), which 
impose subtly different transcriptional programs following scFv/target recognition. 
Differences in persistent or immediate inflammatory activation seem to be well-correlated 
to metabolic function. 41BBz signaling has been shown to impose a metabolic program of 
oxidative phosphorylation, while CD28z signaling favors glycolysis (Kawalekar et al., 
2016). Indeed, this is consistent with published T cell biology in which oxidative 
phosphorylation is associated with long-lived central memory cells (Cui et al., 2015), 
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whereas glycolysis and its production of useful macromolecules is associated with the 
highly inflammatory expansion phase of T cell activation (Buck et al., 2016). Therefore, 
signaling strategies that favor aspects of both effector function and also persistence may 
capture beneficial aspects of both signaling modules. 
 
Section 1.7 – CAR-T Limitations and Advances 
 
Currently, there are many approaches to create “next-generation” CAR-T cells that have 
been proposed.  Several strategies utilize engineered T cells as a source for the 
production of inflammatory molecules, while a number of additional genetic manipulations 
have been proposed to improve intrinsic function of the CAR-T cell itself. Finally, 
approaches targeting multiple tumor antigens have also been proposed to improve 
efficacy in both solid and liquid tumors. Importantly, the vast majority of these approaches 
are focused on improving function of the engineered cells as the primary effector cell for 
tumor clearance. 
 
Section 1.7.1 Persistence and Functional Deficiencies 
A major barrier to T cell function in solid tumors is a suppressive microenvironment 
characterized by anti-inflammatory cytokines, hypoxia, poor nutrient availability, and 
inhibitory ligands (Thommen and Schumacher, 2018). All of these factors enforce a state 
of T cell dysfunction on both endogenous and engineered T cells, and generally favor 
tumor growth.  This is a major barrier to CAR-T cell efficacy and is the focus of a number 
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of engineering strategies designed to enhance persistence of CAR-T cells and therefore 
efficacy of the therapy itself. 
Suppressive cytokines like TGFB and IL10 are produced by Tregs and tumor cells in order 
to limit T cell activation. Novel engineering approaches have demonstrated that the 
presence of these cytokines in the TME may be leveraged through the engineered 
expression of dominant negative or “switch” receptors. In the case of dominant negative 
receptors, suppressive signaling through the wild-type receptor is reduced by 
sequestering the active cytokine in a signaling-dead complex (Kloss et al., 2018). This is 
taken a step further in the case of switch receptors; here a chimeric protein is designed in 
which an inhibitory receptor such as PD1 is connected to an ITAM-containing intracellular 
domain of a costimulatory receptor such as CD28 (Liu et al., 2016a). In this way, a 
naturally suppressive signaling event is converted into a costimulatory signal for the T cell 
and the suppressive environment is interpreted by the cell in a different manner. This is a 
novel strategy, and one could imagine utilizing extracellular domains of suppressive 
cytokine receptors like IL10R or TGFBR (Roth et al., 2020), as well as inhibitory receptors 
like Tim3 or Lag3 with stimulatory intracellular domains of IL12R, MYD88, ICOS, or others. 
While this approach has yet reached the clinic, it represents an elegant solution to several 
adaptive immune resistance mechanisms. 
Beyond switch receptors, genetic deletion of inhibitory proteins has emerged as another 
solution to T cell suppression. The elimination of inhibitory receptors such as PD1 and 
CTLA4 via CRISPR is an attractive and straightforward approach to limit these proteins’ 
effect on engineered T cell activation. Indeed, the first patients were recently treated with 
PD1-edited NYESO-1 T cells in a landmark study for the genome editing field (Stadtmauer 
et al., 2020); these cells were tolerated and demonstrated some increased efficacy, 
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showing this approach may be viable moving forward. In order to affect whole 
transcriptional networks, some groups have proposed that deletion of core transcription 
factors may be even more effective. Notably, the transcription factor Tox, and its’ relatives 
NRA3/NRA4, have been recently shown to control core T cell exhaustion programs (Chen 
et al., 2019; Seo et al., 2019; Yao et al., 2019). Further, deletion of these transcription 
factors in models of adoptive cell therapy (ACT) improved anti-tumor T cell responses, 
demonstrating that such approaches may be translatable to clinical settings. Similar 
results were achieved by deletion of the ribonuclease REGNASE-1, demonstrating that 
multiple pathways contribute to the T cell exhaustion state (Wei et al., 2019). The absence 
of these factors enforces an effector-like state in transferred T cells, which can be similarly 
achieved through overexpression of transcription factors are positively correlated with 
effector T cell function such as c-jun (Lynn et al., 2019). In all, the major goal of these 
strategies is to block the exhausted T cell fate and to instead enforce a more functional 
effector-like transcriptional program with the goal of enhanced function for transferred T 
cells and therefore enhanced efficacy of ACT. 
In addition to direct T cell suppression, solid tumors create poor nutrient environments by 
consuming necessary molecules like glucose at supraphysiological rates. This prevents 
neighboring cells from obtaining normal levels of these molecules. This competition for 
nutrients is exacerbated by irregular blood vessel networks that create zones of poor 
nutrient penetration that favor transformed tumor cells (De Palma et al., 2017). Typically, 
T cells upregulate glycolysis following activation, regardless of nutrient or oxygen 
availability. This is thought to generate both ATP and other macromolecules necessary 
for rapid proliferation and expansion, but requires the consumption of high levels of 
glucose (Buck et al., 2016). Interestingly, this phenomenon was first described in cancer 
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cells, and is known as the “Warburg effect” (Warburg, 1956). Thus, T cells are competing 
with tumor cells for limited nutrients to expand and persist within the TME in order to carry 
out effector functions and control tumor growth. 
A number of strategies are emerging to tilt this competition in favor of T cells. Treatment 
with metabolism-altering drugs such as metformin, which favors fatty acid metabolism, 
improves persistence of T cells (Pearce et al., 2009). In theory this could be used either 
ex vivo during T cell expansion or in vivo following infusion. Similarly, expansion with IL-
15 instead of IL-2 during the expansion phase of CAR-T cell manufacturing favors 
memory-like phenotypes that utilize oxidative phosphorylation (ox-phos) over glycolysis 
and persist more robustly in vivo (Alizadeh et al., 2019), this may also be recapitulated by 
enforcing STAT5-dependent IL7 signaling in engineered cells (Shum et al., 2017). Finally, 
genomic edits in genes such as PPARG and mTOR converge on similar functions and 
enhance ox-phos metabolism and persistence in vivo (Henriksson et al., 2019). A 
combination of these strategies may be optimal, and should be tested for their ability to 
improve engineered T cell function through orthogonal pathways. 
 
Section 1.7.2 Target Heterogeneity 
While strategies to improve T cell function have dramatically advanced in recent years, 
target heterogeneity in solid tumors remains difficult to address and represents a 
significant bottleneck in achieving long-term remissions for patients through cell therapy. 
This problem was not addressed in early CAR-T indications, as CD19 is expressed on 
almost all B cells, both malignant and healthy. Thus, successful CD19-directed CAR-T 
therapy eliminates the healthy B cell repertoire as well as malignant cells (Maude et al., 
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2018). B cell aplasia is a tolerable side-effect given the disease, but this is not the case 
for most solid tumor CAR targets. This is the basis for concern about “on-target, off-tumor” 
toxicity for targets such as mesothelin and Her2. In this case, critical healthy tissues 
express the target antigen, and are attacked by CAR-T cells, which has led to serious 
toxicities (Morgan et al., 2010). Thus, target selection in solid tumors is generally a trade-
off between these toxicities and identification of targets that are not expressed on healthy 
tissues, but are only expressed on a subset of cancer cells (Posey et al., 2016). This is of 
particular concern because multiple cases of CD19-negative leukemic relapse have been 
reported following CD19-directed CAR-T therapy (Gardner et al., 2016; Sotillo et al., 
2015). This antigen-negative relapse mechanism is likely to be much more pronounced in 
solid tumors where a significant number of tumor cells will not be recognized by CAR-T 
cells. Therefore, addressing this problem of target heterogeneity is critical to successful 
therapeutic outcomes, as T cells optimally engineered for persistence and efficacy still will 
not eliminate cells that they do not recognize. 
Strategies to solve this problem thus far have centered around combinatorial targeting. 
For example, “AND-gate” approaches aim to increase safety by requiring two input signals 
to trigger T cell activation. This has been accomplished through inducible promoters 
(Roybal et al., 2016), separation of activation domains (He et al., 2020), and 
pharmacological triggers (Wu et al., 2015). Alternatively, many groups have developed 
so-called “universal” CAR-T cells that recognize a common domain added to a repertoire 
of antibodies with varying specificity. For example, replacing the scFv domain of a CAR 
molecule with a domain that recognizes biotin (Lohmueller et al., 2017), an engineered Fc 
region (Rodgers et al., 2016), or leucine zipper (Cho et al., 2018) will trigger CAR-T 
activation. Engineered antibodies that bind several different tumor targets can then be 
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administered and antibody-bound tumor cells will be recognized by a single CAR-T cell 
product specific to the engineered constant region of the antibody. This approach seeks 
to overcome the heterogeneity problem by targeting multiple antigens at once, but is still 
limited by target validation, engineering capacity, and antibody diffusion kinetics. Finally, 
approaches centered around CAR-T infusion products containing multiple CAR-T 
specificities might overcome heterogeneity problems, but regulatory hurdles make this 
approach unlikely in the clinic. Even with optimal engineering, these approaches are 
limited to a repertoire on the order of 10
1
 targets, and are therefore unlikely to achieve 
clearance of highly heterogenous tumors. Alternatively, the endogenous T cell repertoire 
can theoretically encode 10
15
 specificities (Laydon et al., 2015); this makes strategies that 
leverage endogenous immunity a particularly attractive approach for solving the 
heterogeneity problem. 
 
Section 1.8 – Unresolved questions 
 
Because of conflicting reports around the role of inflammation in the TME, a central goal 
of the field is to identify contexts that determine whether the activation of inflammatory 
pathways such as IFNG and IFN-I drives tumor resistance or response to ICB therapy. 
The existing data on this subject reviewed here suggest that this is likely dependent on a 
combination of antigen availability, MHC-I expression, and effector cell activation. Chapter 
2 of this thesis will outline a mechanistic framework for how we believe IFNG affects these 




IFNG is produced mainly by the adaptive immune system. This response becomes 
engaged when the innate immune system is alerted to danger, a process traditionally 
mediated by PRR activation. Similar to inflammatory responses generated by the adaptive 
immune system, the role for context and localization of PRR signaling has not been well 
defined in the regulation of anti-tumor immune responses. In Chapter 3, we provide a 
framework based on cellular localization of these signals to explain pro- and anti-tumor 
effects of PRR signaling. Further, we outline a novel cell therapy approach to leverage 
these findings in syngeneic solid tumor models. These experiments provide a rationale for 
novel cell engineering approaches and provide insight into a crucial role for localization of 
PAMP signaling in the TME. In total, this thesis will outline a framework for understanding 
the contexts in which inflammatory signaling is beneficial or detrimental to anti-tumor 







CHAPTER 2 – OPPOSING FUNCTIONS OF INTERFERON COORDINATE ADAPTIVE 
AND INNATE IMMUNE RESPONSES TO CANCER IMMUNE CHECKPOINT 
BLOCKADE 
 
Section 2.1 – Introduction 
 
Immune checkpoint blockade (ICB) of the inhibitory receptors CTLA4 and PD1 can result 
in durable responses in multiple cancer types (Ribas and Wolchok, 2018). Resistance and 
relapse are common and can be influenced by factors inherent to immune cells, cancer 
cells, or both (Patel and Minn, 2018). Important immune features include the status of T 
cell infiltration and the differentiation or activation state of T cells and innate immune cells. 
Features intrinsic to cancer cells that can impact ICB outcome include their repertoire of 
neoantigens, the ability to present antigens on major histocompatibility complex class one 
(MHC-I), and the expression of inhibitory receptor ligands. The clinical relevance of these 
immune and cancer cell factors is highlighted by common biomarkers for ICB response 
such as type I or II interferon (IFN) stimulated genes (ISGs) (Ayers et al., 2017; Harlin et 
al., 2009), tumor mutational burden (TMB) (Rizvi et al., 2015; Snyder et al., 2014), and 
expression of PDL1 (Taube et al., 2012; Tumeh et al., 2014). 
Both IFN-gamma (IFNG) and Type I IFN (IFN-I) are among the known pathways that have 
critical roles in anti-tumor immunity. IFN enhances immune function by inducing 
expression of MHC-I (Dighe et al., 1994), which is constitutively expressed on many 
tissues including cancer cells, and by enabling dendritic cells (DCs) to cross prime T cells 
(Diamond et al., 2011; Fuertes et al., 2011). In this way, IFNs are important in the early 
phase of antigen recognition and the interaction between adaptive and innate immune 
cells. Accordingly, loss-of-function mutations and genomic alterations in the IFN signaling 
pathway have been associated with clinical ICB resistance and/or relapse (Gao et al., 
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2016; Shin et al., 2017; Zaretsky et al., 2016), and unbiased genetic screens have 
identified this same pathway as being important for immunotherapy response in certain 
mouse models (Manguso et al., 2017; Mezzadra et al., 2017). In contrast, some patients 
have tumors with mutations in the IFN pathway that nonetheless respond to ICB 
(Hellmann et al., 2018; Sade-Feldman et al., 2017) or have high serum levels of IFNG that 
associates with ICB progression (Huang et al., 2017). These apparently “paradoxical” 
observations may represent feedback inhibition properties of IFN signaling (Snell et al., 
2017). In the context of chronic pathogen infection, persistent IFN signaling and ISGs 
dampen immune responses to prevent immune-mediated pathology while allowing for a 
host-pathogen stalemate (Cheng et al., 2017; Teijaro et al., 2013; Wilson et al., 2013). In 
cancer, this dichotomous function of IFN is exploited through chronic signaling by tumor 
cells that can promote resistance to ICB (Benci et al., 2016). IFN-driven resistance can be 
inhibited by genetic ablation of the IFNG receptor (IFNGR) and/or IFN-I receptor (IFNAR) 
in cancer cells, resulting in a decrease in PDL1, other inhibitory ligands, and the GzmB 
antagonist SERPINB9  (Jiang et al., 2018). Expansion of exhausted T cells (TEX) can then 
ensue to restore ICB response through unknown mechanisms. Together, these 
observations highlight the importance of understanding how the opposing functions of IFN 
signaling impact cancer immunotherapy. 
Loss of the beta-2 microglobulin (B2M) subunit of MHC-I appears to be a common 
resistance mechanism to ICB (Sade-Feldman et al., 2017). However, diminished 
expression or loss of B2M can also occur in patients who respond to ICB (Rizvi et al., 
2018; Rodig et al., 2018), suggesting that innate immune cells might contribute to ICB 
response in some cases. Indeed, conventional NK cells and innate lymphoid cells (ILCs) 
are capable of destroying cancers through either perforin-mediated cytotoxicity or TNF-
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family death receptors such as TRAIL (Spits et al., 2016). NK/ILC effector function is 
regulated through cellular maturation, combinations of activating and inhibitory receptors, 
and possibly immune checkpoint receptors like PD-1, TIM3, and TIGIT (Gao et al., 2017; 
Zhang et al., 2018). Recent evidence indicates that type one ILCs (ILC1s) can participate 
in anti-tumor immunity or cancer immune surveillance. This includes ILC1-like populations 
(Dadi et al., 2016) and intratumoral ILC1s that are generally poorly cytotoxic (Cortez et al., 
2017; Gao et al., 2017). Although the ability of NK/ILC1s to eradicate tumors with 
diminished MHC-I and/or a poor neoantigens is of significant interest, how to mobilize 
these innate immune cells to facilitate tumor response is unclear. 
 
Section 2.2 – ISGs Expressed by Cancer Cells Predict Resistance to Immune 
Checkpoint Blockade while ISGs Expressed by Immune Cells Predict Response 
 
A large proportion of human cancers differentially express a subset of ISGs that can 
predict resistance to radiation and chemotherapy (Weichselbaum et al., 2008). 
Coincidentally, this ISG resistance signature (ISG.RS) is also associated with resistance 
to ICB, as demonstrated by elevated expression in murine tumors from Res 499 
melanoma cells (Benci et al., 2019), which were derived from an ICB-resistant B16-F10 
tumors (Twyman-Saint Victor et al., 2015). In contrast, ISGs can also predict clinical ICB 
response, especially ISGs typically associated with IFNG signaling (Ayers et al., 2017). 
To begin reconciling these seemingly disparate observations, we examined the ISG.RS 
and genes from the IFNG hallmark gene set (IFNG.GS) by dividing them into two non-
overlapping subsets (Figure 2.1A) and creating a metagene (the average scaled 
expression of all genes in the set). The expression of these ISG metagenes was then 
examined across different cellular populations in human melanomas using previously 
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published single-cell RNA-seq data (Tirosh et al., 2016). This revealed that the IFNG.GS 
is predominantly expressed by intratumoral immune cells such as T cells, NK cells, and 
macrophages. In contrast, the ISG.RS is predominantly expressed in cancer cells, albeit 
with variable expression (Benci et al., 2019).  
To understand the potential consequences of these differences in IFNG.GS and ISG.RS 
expression patterns, we analyzed bulk RNA-seq data combined from two cohorts of 
melanoma patients treated with anti-PD1 (Hugo et al., 2017; Riaz et al., 2017). As 
expected, the majority of genes in the IFNG.GS are depressed in the majority of tumors 
from non-responders to anti-PD1. However, like ICB-resistant murine Res 499 tumors, 
most ISG.RS genes are enriched in tumors from non-responders. Consistent with the 
importance of CD8
+
 T cells in response, tumors with high IFNG.GS but low ISG.RS also 
have the greatest proportion of CD8
+
 T cells as inferred by CIBERSORT (Newman et al., 
2015). The higher frequencies of CD8
+
 T cells are accompanied by increased number of 
activated NK cells, which also has been associated with clinical ICB response (Riaz et al., 
2017). To understand how these immune and interferon-related variables independently 
contribute to ICB response, we utilized a multivariable logistic regression model. This 
revealed that while higher IFNG.GS increases the odds ratio for response, ISG.RS 
independently decreases the likelihood. The significance of both of these variables are 
independent of tumor mutational burden (TMB) status, which expectedly correlates with 
response. In contrast, neither the abundance of CD8
+
 T cells nor NK cells are significant 
in the model. In total, these data suggest that while expression of IFNG.GS by immune 
cells is associated with CD8
+
 T cell abundance, accumulation of activated NK cells, and 
ICB response, all of these effects are opposed by high levels of ISG.RS in cancer cells 
(Benci et al., 2019). 
42 
 
Although the IFNG.GS and ISG.RS predict opposite clinical outcomes, their expression is 
positively correlated, consistent with IFN controlling both metagenes (Figure 2.1B). An 
explanation for this apparent ‘‘paradox’’ lies in the relative expression of each metagene. 
When expression of the ISG.RS exceeds the IFNG.GS, resistance is favored (Figure 2.1B, 
left plot, red circles below diagonal). In contrast, most responses occur when IFNG.GS is 
similar to or greater than ISG.RS (Figure 2.1B, blue circles). Based on these findings, we 
combined the two metagenes into a ratio of IFNG.GS over ISG.RS (or, the difference of 
these two metagenes in log transformed space). By logistic regression, this composite 
variable (dISG) is strongly associated with response and is independent of TMB (Figure 
2.1B, right plot and inset). Specifically, the probability of response is low when either the 
ratio or TMB is low but increases when either increase. Furthermore, random forest 
machine learning and bootstrapping revealed that the ISG ratio has the highest robustness 
and average variable importance compared to TMB and multiple immune features (data 
not shown, (Benci et al., 2019)). 
In total, the single-cell and bulk RNA-seq analysis suggests that distinct ISGs differentially 
expressed by cancer and immune cells can oppose each other to influence CD8
+
 T cell 
infiltrate and NK activation and can be combined into a ratio that predicts ICB response 
independent of TMB (Figure 2.1C). Motivated by these findings, we sought to understand 
the mechanistic underpinnings inferred by these statistical relationships. 
 
Section 2.3 – Models Differing in MHC-I, TMB, and Neoantigen Status for 




If the probability of ICB response is influenced by the ratio of IFNG-related ISGs expressed 
by immune cells to inhibitory ISGs expressed by cancer cells, one way to enhance the 
ratio in favor of response is to prevent IFN signaling in cancer cells. We first confirmed 
whether the ISG.RS, which is elevated in ICB-resistant Res 499 tumors, is regulated by 
IFN signaling in cancer cells (hereafter referred to as tumor IFN signaling). Indeed, 
CRISPR knockout of IFNGR and/or IFNAR significantly diminishes ISG.RS levels (Benci 
et al., 2019). However, loss of tumor IFN signaling can render cancers less responsive to 
immunotherapy due to compromised MHC-I and antigen processing (Manguso et al., 
2017; Zaretsky et al., 2016) suggesting that the impact from ablating tumor IFN signaling 
might be context dependent. In light of this, we surmised two situations whereby the 
benefit of inhibiting IFN-driven resistance could outweigh the potential negative impact on 
MHC-I. The first is when constitutive MHC-I is high, minimizing effects that loss of IFN-
inducible MHC-I has on CTL-mediated killing. A second situation is when tumors have 
depleted or poor neoantigens. Here, diminished CTL recognition presumably makes MHC-
I status less consequential for T cell-mediating killing, but interference with IFN-driven 
resistance might improve killing by NK or other innate lymphoid cells. 
We first characterized various mouse tumor models for differences in MHC-I expression, 
TMB, and predicted neoantigen status (Figure 2.1D). Of these, CT26 colorectal cancer 
has the highest TMB, and maintains high MHC-I in the absence of IFNG signaling (Figures 
2.1E and 2.1F). Similarly, TSA-derived Res 237 breast cancer cells also have high IFNG-
independent baseline MHC-I but exhibit lower TMB (Figure 2.1D). In contrast, B16 and/or 
Res 499 melanoma have intermediate TMB and low constitutive MHC-I and rely on IFNG 
for high MHC-I expression (Figure 2.1D-F). Since Res 499 originated from an abscopal 
B16 tumor that relapsed several weeks after radiation (RT) plus anti-CTLA4 (Twyman-
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Saint Victor et al., 2015), we surmised that Res 499 may additionally have undergone 
immunoediting prior to relapse. Recent evidence suggests that neoantigens that have 
clonal or near-clonal representation are predominantly targeted by the immune system, 
while neoantigens at low clonal fractions can remain immunologically silent (Gejman et 
al., 2018; McGranahan et al., 2016). In accord with this notion, there is a significant 
decrease in the cumulative frequency of predicted high affinity (< 100 nM) neoantigens 
with clonal (near-heterozygous or greater) frequencies in Res 499 compared to B16 (Benci 
et al., 2019). Together, these data define several tumor models that differ in reliance on 






Figure 2.1. Distinct ISGs are differentially expressed in cancer and immune cells 
and have opposing functions in predicting clinical ICB response. A) Venn diagram 
of genes in the cancer-associated ISG.RS along with immune-associated hallmark 
IFNG-related genes (IFNG.GS) partitioned into non-overlapping gene sets (color-
coded) and used to create individual metagenes. B) Expression of each metagene (left 
plot), and the predicted probability of anti-PD1 response (right plot) from a model using 
TMB and the ratio of IFNG.GS over ISG.RS (dISG). Odds ratios are shown in the inset. 
Circle color indicates response and size indicates TMB. C) Summary of cancer and 
immune cell relationships inferred by statistical modeling and how ISGs impact 
probability of ICB response. D) Summary of key properties of mouse tumor models. 
N.D. is not determined. E) Constitutive (baseline) and F) IFNG-inducible (+IFNG) MHC-
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Section 2.4 – Blocking Tumor IFN Signaling Broadly Improves ICB Response 
through CD8+ T and Innate Immune Cells 
 
We first used the CT26 model to examine whether tumors with high constitutive MHC-I 
and TMB demonstrate improved response when ISG.RS is decreased by blocking tumor 
IFN signaling. Remarkably, when IFNGR or both IFNGR and IFNAR are ablated, mice 
either show markedly slower tumor growth or spontaneous regression that is CD8
+
 T cell 
dependent (Figure 2.2A), as determined by antibody-mediated depletion (Figure S2.2A). 
The addition of anti-PD1 further improves anti-tumor effects and survival. Both 
spontaneous regression and durable response to anti-PD1 requires B2M and hence MHC-
I. All mice with complete response are also resistant to tumor rechallenge (8 out of 8 mice), 
further indicative of a T cell dominant response. Thus, decreasing ISG.RS by preventing 
IFN signaling in tumors with high baseline MHC-I does not interfere with CTL-mediating 
killing and markedly enhances immunogenicity. 
Unlike CT26, B16 cells are reliant on IFN for high MHC-I expression. B16 tumors respond 
poorly to anti-PD1 but respond to RT + anti-CTLA4, a combination that enhances T cell 
repertoire diversity and improves response over anti-CTLA4 alone (Twyman-Saint Victor 
et al., 2015). Surprisingly, knockout of IFNGR and IFNAR in B16 tumors does not 
negatively impact the efficacy of RT + anti-CTLA4 (Figure 2.2B, top left plots, red versus 
orange), suggesting that other immune-mediated killing mechanisms may compensate for 
low MHC-I and compromised CTL recognition in this context. Indeed, partial response of 
IFNGR + IFNAR knockout tumors to RT + anti-CTLA4 is maintained even after B2M is 
ablated (Figure 2.2B, top left plots, gray versus light blue). However, when B2M knockout 
is accompanied by depletion of NK1.1
+
 cells (Figure S2.2A), which are typically 
conventional NK cells and ILC1s, response is completely eliminated (Figure 2.2B, left top 
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and bottom plots, gray versus red). In contrast to B16, Res 499 tumors are resistant to RT 
+ anti-CTLA4 and have relative depletion of predicted neoantigens. Despite this, knockout 
of IFNGR and IFNAR restores Res 499 response to levels at least as high as parental B16 
tumors (Figure 2.2B, right plots). Consistent with loss of neoantigens and reliance on 
innate immune killing, co-ablation of B2M has no discernible effect, while depletion of 
NK1.1
+
 cells alone abrogates the benefit from IFNGR + IFNAR knockout (Figure 2.2B, 
right top and bottom plots). However, if the requirement for high MHC-I and antigen is 
bypassed by using a murine chimeric antigen receptor (CAR) T cell against ectopically 
expressed human CD19 (Figure S2.2B), blocking tumor IFN signaling similarly improves 
response of both B16 and Res 499 tumors (Figure 2.2C). In the absence of CAR-T cells, 
IFNGR + IFNAR knockout tumors grow similarly to control (Figure S2.2C). Thus, blocking 
tumor IFN signaling can impact both CD8
+
 T cell and NK/ILC1 effector function. 
In total, these data suggest that blocking tumor IFN signaling can improve T cell-mediated 
killing when antigen recognition is not limited by inhibiting IFN function, as in the case of 
CT26 tumors or use of CAR-T cell therapy. In tumors with low MHC-I, preventing tumor 
IFN signaling may compromise CTL-mediated recognition but anti-tumor effects of 
NK/ILC1s can compensate to maintain response, as in the case of B16 tumors. In tumors 
such as Res 499 that are highly resistant and otherwise poorly recognized by T cells, the 
dispensability of MHC-I allows for restored response through NK/ILC1-mediated killing. 
Section 2.5 – Inhibition of Tumor IFNG Signaling Enables CD8+ T cells to Support 
NK/ILC1-Mediated Killing 
 
 To understand how blocking tumor IFN signaling restores ICB response in 
resistant or relapsed tumors and to avoid conflating effects of type I and II IFN, we focused 
on how IFNGR knockout restores response in the Res 499 model. We also opted to use 
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anti-CTLA4 monotherapy given that addition of RT does not significantly improve 
response over anti-CTLA4 alone (Figure 2.2D versus 2.2B). As expected for NK/ILC1-
mediating killing, IFNGR knockout improves response to anti-CTLA4 in the absence of 
B2M and requires NK1.1
+
 innate immune cells (Figures 2.2D and S2.2D, credit-Joseph 
Benci). Interestingly, this response is also abrogated in the absence of CD8
+
 T cells, 
despite a lack of B2M on tumor cells. Thus, like with inhibition of both type I and II IFN 
signaling, blocking tumor IFNG signaling can restore ICB response by enhancing 
NK/ILC1-mediated effector function, likely through enhanced effector function supported 
by CD8
+
 T cells. 
A similar requirement for both CD8
+
 T cells and NK/ILC1s is also observed after IFNGR 
knockout in the resistant TSA/237 breast cancer model that exhibits relatively low TMB 
and a paucity of predicted strong neoantigens (Figures 2.1D and S2.2E). These 
observations suggest that although CD8
+
 T cells do not directly kill IFNGR knockout Res 






Figure 2.2. Preventing tumor IFN signaling promotes CD8+ T cell-dependent 
and/or NK/ILC1-dependent ICB response. A) Survival of mice bearing CT26 tumors 
with KO of IFNGR +/- B2M or of both IFNGR and IFNAR (IFNA/GR) after no treatment 
(Cont), CD8 depletion (aCD8), or anti-PD1 (anti-PD1). For each group, n=5-15. B) 
Survival (top) and tumor volumes (bottom) after treatment with RT + anti-CTLA4 or 
control (Cont) for mice bearing B16 or Res 499 tumors with the indicated KO. Unless 
indicated, displayed p-values are for comparisons within each genotype (legend). For 
tumor volumes, only groups of interest are shown. Groups with no depletion: WT, n=20-
28; IFNA/GR KO, n=10-20; IFNA/GR + B2M KO, n=4-5. For aNK1.1 groups, n=5. C) 
Tumor volumes for B16 and Res 499 tumors expressing human CD19 (hCD19) with or 
without IFNA/GR KO after a single infusion with primary murine T cells transduced with 
a CAR (CART) against hCD19. D) Survival of mice bearing IFNGR KO Res 499 tumors 
with or without concurrent B2M KO after treatment with anti-CTLA4. Effect of immune 
cell depletion with anti-CD8 or anti-NK1.1 is shown. IFNGR KO, n=5; B2M KO, n=5; 
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Supplemental Figure 2.2. Immune cell requirements for response after IFNGR 
knockout, Related to Figure 3. A) Representative density plots of tumor infiltrating 
CD45
+




 after control (top) or depletion with 
anti-NK1.1 (bottom left) or anti-CD8 (bottom right). B) Ectopic expression of human 
CD19 on B16 and Res 499 melanoma cells. C) Tumor growth of B16 and Res 499 
tumors expressing human CD19 with (IFNA/GR KO) and without (Cont) concurrent 
IFNGR + IFNAR knockout. D) Baseline and IFNG-inducible expression of MHC-I and 
PDL1 on Res 499 cells with or without knockout of IFNGR and/or B2M. E) Survival of 
mice bearing TSA/Res 237 tumors with IFNGR knockout after anti-CTLA4 and prior 
depletion of CD8
+
 T cells or NK/ILCs with either anti-CD8 (aCD8) or anti-Asialo-GM1 





 intratumoral immune cells after control and depletion with anti-Asialo-
GM1. 
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Section 2.6 – Preventing Tumor IFNG Signaling Enhances Immune Cell IFNG 
Signaling, CD8+ TEX Function, and Maturation of NK/ILC1 Cells 
 
 To examine how CD8
+
 T cells might support NK/ILC1s, we employed single-cell 
RNA-sequencing (scRNA-seq) and 28-color flow cytometry. Analysis of intratumoral 
CD45
+
 immune cells by scRNA-seq revealed that a dominant effect of tumor IFNGR 
knockout is an increase in the proportion of CD8
+
 T cells (Figure 2.3A). Intratumoral CD8
+
 
T cells are typically exhausted and reside in either a progenitor exhausted or terminally 





cells have limited long-term proliferative potential, they can carry out various effector 
functions such as cytotoxicity and IFNG production (Miller et al., 2019; Paley et al., 2012). 
Gene set enrichment analysis (GSEA) using transcriptional signatures of these exhausted 
subsets (defined using the LCMV infection model) revealed that the expanded CD8
+
 T 
cells resulting from IFNGR knockout show a marked increase in terminal exhaustion 
genes (e.g., Pdcd1, Eomes, Cd38) and a decrease in progenitor exhaustion genes (e.g., 
Tcf7) (Figures 2.3B and S2.3A). Accordingly, there is a per cell increase in the amount of 




 T cells, and after anti-CTLA4 there is a large 
increase in IFNG per gram of tumor (Figures 2.3C and S2.3B), which is not observed with 
cytokines such as IL-6 (Figure S2.3C, credit-Joseph Benci). Depletion of CD8
+
 T cells 
largely abrogates this intratumoral increase in IFNG, highlighting the importance of 
exhausted CD8
+
 T cells in generating this cytokine. Accompanying the increase in IFNG 
is a marked increase in the IFNG.GS primarily from myeloid/DC populations (Figure 2.3D). 
Among various IFNG.GS genes that increase include Cxcl9 and Cxcl10 (Figure 2.3E), 
which are chemokines implicated in NK cell recruitment, activation, or maturation (Pak-
Wittel et al., 2013). Thus, disrupting tumor IFNG signaling not only decreases the ISG.RS 





cells. As an apparent consequence, myeloid/DC populations increase expression of 
IFNG.GS that include chemokines important in innate immune function. 
In order to investigate how preventing IFNG signaling in tumor cells impacts NK/ILC1 
status, we re-clustered NK/ILC1 populations identified by scRNA-seq (Figure 2.3F-G). 
This revealed NK populations differing in maturity and effector function (Chiossone et al., 
2009), including an immature CD11blow population, an intermediate CD11bint population, 
and a mature CD11bhigh cluster that typically possesses the greatest effector function. 
Moreover, recently described ILC1 and intermediate ILC1 (intILC1) populations (Cortez et 
al., 2017; Gao et al., 2017) were also identified (Figure S2.3D). Knockout of tumor IFNGR 
results in a large shift in the NK populations toward the mature CD11b-high cluster and an 
additional shift toward the ILC1 cluster (Figure 2.3F, density plots). These ILC1s exhibit 
relatively high levels of Pd1 (Pdcd1) and TRAIL (Tfnsf10) (Figure 2.3G), consistent with 
previously reported properties for this population. Using 28-color flow cytometry (Figures 
S4E and S4F), we confirmed that tumor IFNGR knockout leads to an increase in the 
proportion of NK/ILC1s that are CD11bhigh NK cells or PD1+ TRAIL+ ILC1s (Figures 
2.3H–4I and S2.2G). Flow cytometry also confirmed that this is accompanied by an 
increase in the proportion of terminally exhausted CD8
+
 T cells, particularly after anti-






 T cells that express multiple 
inhibitory receptors and relatively high levels of Ki67 and GzmB (Figures 2.3H and S2.3G). 
Together, these results indicate that preventing tumor IFNG signaling expands CD8
+
 TEX 
toward terminal exhaustion and increased production of IFNG. In this way, disrupting 
tumor IFNGR not only decreases ISG.RS in cancer cells but conversely increases 
IFNG.GS expression by immune cells. This enhanced IFNG signaling in immune cells 
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might then drive maturation and function of NK/ILC1 subsets, including a PD1+ TRAIL+ 




Figure 2.3. Blockade of tumor IFNG signaling promotes CD8+ TEX expansion, 
IFNG production, immune cell IFNG signaling, and maturation of NK and PD1+ 
TRAIL+ ILC1 cells. CD45+ immune cells from Res 499 tumors with or without IFNGR 
KO were profiled by scRNA-seq. A) tSNE plot with identified immune populations (left) 
and corresponding density plots (right). The percent of CD8
+
 T cells is 6.4% and 16.8% 
in wild type (WT) and IFNGR KO tumors, respectively.  B) GSEA on CD8+ T cell 
clusters using T cell terminal exhaustion and progenitor exhaustion gene sets. C) 
Intratumoral IFNG protein levels from wild type or IFNGR KO Res 499 tumors treated 
with or without anti-CTLA4. Effect of CD8
+
 T cell depletion (aCD8) is also shown. D) 
Expression of IFNG.GS or E) average expression of Cxcl9 and Cxcl10 across 
intratumoral immune cells from wildtype or IFNGR KO tumors overlaid on the tSNE 
map shown in (A). F) NK1.1+ and NKp46+ NK cell clusters from (A) were re-clustered. 
Shown is a tSNE plot with identified NK and ILC1 populations (left) and corresponding 
density plots (right). G) Average expression of select NK/ILC1 genes for each of the 
indicated NK or ILC1 maturation stage. H) CD8+ T cells and NK/ILC1 populations were 

















 TEX (left) or the 
proportion of CD11b
hi




 ILC1 cells relative to total NK/ILC1s (right). 
I) Density plots of NK/ILC1 clusters and expression of indicated markers overlaid onto 
a tSNE plot. Points are colored by scaled MFI and overlaid with a contour plot. Clusters 
3, 9, 10, and 11 are CD11b
hi




 ILC1 cells. See 
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Supplemental Figure 2.3. Improved TEX function and NK/ILC1 maturation after 
blocking tumor IFNG signaling, Related to Figure 2.3. A) Violin plots showing 
expression of the indicated genes in CD8
+
 T cells from Res 499 wild type (WT) or 







 T cells and C) intratumoral IL6 protein levels from wild type or 
IFNGR knockout Res 499 tumors treated with or without anti-CTLA4. Effect of antibody-
mediated CD8
+
 T cell depletion (aCD8) on IL6 levels was also examined. D) GSEA 
comparing ILC1 cluster to other NK cell clusters using genes increased or decreased 
in ILC1s relative to conventional NK cells. E) Dimensionality reduction and cluster 









Shown are heatmaps of the scaled MFI for each of the indicated markers across the 
identified clusters (labels below heatmap). For CD8
+





 TEX are denoted in red. For NK/ILC1s, clusters in red denote CD11b
high
 innate 
immune cells. F) Contour plots showing the distribution of CD8+ T cells after anti-
CTLA4 (top) or of NK/ILC1s at baseline (bottom) in either wildtype or IFNGR knockout 
Res 499 tumors. Individual cells corresponding to the contour plot are overlaid and 
colored by the scaled MFI of the indicated marker. G)  Density plots of CD8+ T cells or 
NK/ILC1s in wildtype or IFNGR knockout Res 499 tumors treated with or without anti-
CTLA4. The left plot is a tSNE map. For CD8
+





with low or high expression of GzmB and Ki67 are color-coded and numbered. For 
NK/ILC1s, clusters enriched for CD11b
high




 ILC1 cells are color-
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Section 2.7 – Preventing Tumor IFNG Signaling Enables IFNG from CD8+ TEX to 
Drive NK/ILC1 Function while Removing Inhibitory Feedback from PD1/PDL1 
 
Given the single-cell findings, we sought to investigate whether IFNG produced by CD8
+
 
TEX is involved in NK/ILC1-mediated killing and whether the PD1/PDL1 pathway can 
contribute to response after IFNGR knockout. To test the role of IFNG produced by CD8
+
 
T cells, we adoptively transferred CD8
+
 T cells from wild-type or IFNG knockout mice into 
RAG-deficient hosts and then implanted the mice with Res 499 IFNGR knockout tumors. 
This revealed that IFNG production by CD8
+
 T cells is required for anti-CTLA4 response 
(Benci et al., 2019). Conversely, when CD8
+
 T cells are depleted, there is a decrease in 
the proportion of mature CD11b
+
 NK/ILC1s, as well as total NK/ILC1s (Figure 2.4A). 
However, direct intratumoral injection of IFNG or CXCL10 can rescue or partially rescue 
the loss in NK/ILC1 cells (Figure 2.4B). NK/ILC1-dependent ICB response and survival 
that is also compromised after depleting CD8
+
 T cells is similarly rescued by injection of 
IFNG (Benci et al., 2019). Thus, these results suggest NK/ILC1-dependent response 
resulting from blocking tumor IFNG signaling relies on IFNG produced by CD8
+
 TEX and 
on downstream chemokines such as CXCL10. 
Although IFNG has a critical role in promoting NK/ILC1 function, it also induces high levels 
of PDL1 on tumors. Given that PD1 is expressed on ILC1 cells, this suggests that the 
PD1/PDL1 axis may normally function as an IFNG-directed feedback inhibition 
mechanism to antagonize innate immune function, similar to its role in regulating T cell 
responses. If so, removal of this feedback inhibition by IFNGR knockout may contribute to 
the improved response resulting from blocking tumor IFNG signaling. To examine this, we 
ectopically expressed PDL1 in PDL1 knockout Res 499 tumors to make PDL1 levels 
independent of IFNG signaling. In contrast to wild-type or B2M-deficient Res 499 tumors, 
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the ability of IFNGR deletion to improve anti-CTLA4 response is lost when PDL1 levels 
are fixed (Benci et al., 2019). To remove effects of PD1 from CD8
+
 T cells, we depleted 
CD8
+
 T cells but restored NK/ILC1 function in IFNGR-deficient Res 499 tumors by 
intratumoral administration of IFNG (Figure 2.4C, red boxplots). Consistent with tumor 
PDL1 inhibiting NK/ILC1 killing, fixing high PDL1 expression despite IFNGR knockout 
blunted NK/ILC1-dependent ICB response. The notion that PD1/PDL1 can directly inhibit 




 liver NK cells cultured with 
IFNGR-deficient Res 499 cells with and without ectopic PDL1 (Benci et al., 2019). In total, 
these results suggest that tumor IFNG signaling normally drives feedback inhibition 
through tumor PDL1 to regulate NK/ILC1 function. Thus, ablating tumor IFNGR not only 
increases immune cell IFNG signaling but also enhances innate immune killing by 






Figure 2.4. NK/ILC1-mediated killing from blocking tumor IFNG signaling is 
regulated by IFNG produced by TEX and PDL1. A) Proportion of mature CD27– 
CD11b
+ 
NK/ILC1s in Res 499 tumors after CD8
+
 T cell depletion (aCD8). 
Representative flow cytometry contour plots are shown. B) Mice bearing IFNGR KO 
Res 499 tumors were depleted of CD8
+
 T cells followed by intratumoral injection of the 
indicated cytokine. Shown is the percentage of intratumoral CD8
+
 T cells and 
NK/ILC1s. C) Response of IFNGR KO Res 499 tumors in CD8+ T cell-depleted mice. 
Mice were treated with anti-CTLA4 with or without intratumoral injection of IFNG. Effect 
of concurrent depletion of NK/ILC1s with anti-NK1.1 is also shown as well as effect of 
high constitutive PDL1 on IFNGR KO tumors (red boxplots). Tumor volumes are 
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Section 2.8 – Adaptive Immune Cell Requirements for Innate Immune Cell Killing 
After Blocking Tumor IFNG Signaling  
 
Despite our findings that response after IFNGR knockout of Res 499 tumors requires IFNG 
produced by CD8
+
 T cells, the dispensability of tumor MHC-I argues that antigen 
presentation by tumor cells is not necessary for CD8
+
 TEX to support NK/ILC1 function. To 
corroborate this, we implanted Res 499 tumors deficient in both IFNGR and B2M in either 
wild-type mice or OT-1 mice expressing a transgenic T cell receptor to OVA antigen, which 
is not expressed by Res 499 tumors. The accumulation of both intratumoral CD8
+
 T cells 
and NK/ILC1s is reduced and ICB response is lost in OT-1 mice compared to wild-type 
mice. However, intratumoral injection of OVA peptide rescued the compromised CD8
+
 T 
cell frequency and partially restored NK/ILC1 levels. Moreover, despite the absence of 
tumor MHC-I, response to anti-CTLA4 was also partially rescued. Thus, the ability of 
IFNGR knockout to enhance NK/ILC1-dependent ICB response need not depend on 
antigen presentation by tumor cells themselves. Rather, cross-primed and/or activated 
bystander T cells can suffice (Benci et al., 2019). 
Section 2.9 – Tumor Mutations in IFN Pathway Genes Predict Clinical Response to 
Dual Blockade of PD1 and CTLA4 
 
  Our findings suggest that mutations predicted to reduce tumor IFN signaling might 
associate with decreased ISG.RS and improved clinical response to ICB. To investigate 
this, we extended the analysis of recently described exome-sequencing data of non-small 
cell lung cancer (NSCLC) patients from either TCGA or a clinical trial using anti-PD1 plus 
anti-CTLA4 (Hellmann et al., 2018). After excluding common non-disease single-
nucleotide variants, pathogenic missense and nonsense mutations were predicted using 
two algorithms, CADD and DANN, that were trained on a catalog of benign and pathogenic 
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variants from the ClinVar database. Indels were also evaluated as damaging or neutral 
using SIFT. In the TCGA, there is an 8.6% incidence of patient tumors with at least one 
predicted pathogenic variant in a core set of 11 type I and II IFN pathway genes (Benci et 
al., 2019). These tumors exhibit a decrease in ISG.RS genes, consistent with an 
enrichment for IFN pathway variants with defective signaling (Figure 2.5A). In the patients 
treated with anti-PD1 plus anti-CTLA4, 14.7% of patients have at least one IFN pathway 
variant and these patients have improved progression-free survival (PFS) with dual ICB 
(Figures 2.5B). In contrast, only 0.58% of random gene sets of similar size yield PFS 
differences that are as significant, and IFN pathway variants do not associate with survival 
in TCGA patients (data not shown), arguing that variant status is not a general prognostic 
marker. Notably, despite a higher likelihood of response, variant-positive tumors exhibit 
lower percent tumor PDL1 expression (5.4% versus 20.3%; Figure 2.5C, credit-Wolchok 
laboratory), consistent with variants having a negative impact on tumor IFN signaling. In 
contrast, stratification by variant status of random genes rarely yields a difference in % 
PDL1 this large (data not shown). Notably, one patient had a tumor with multiple alleles of 
B2M with a frameshift indel or predicted pathogenic missense mutations who nonetheless 
had a PR to ICB (Benci et al., 2019). This is consistent with previous reports describing a 
NSCLC patient responding to anti-PD1 despite deleterious B2M mutations and loss of 
B2M expression confirmed by immunohistochemistry (Rizvi et al., 2018). Thus, genetic 
alterations of the IFN pathway in human NSCLC are associated with decreased ISG.RS, 







Figure 2.5. Tumor mutations in the IFN pathway predict decreased ISG.RS and 
increased survival in lung cancer patients treated with anti-CTLA4 and anti-PD1. 
A) GSEA of ISG.RS genes comparing TCGA NSCLC patients with and without a 
predicted pathogenic variant in the IFN pathway (IFN Path Var). B) Progression-free 
survival after anti-CTLA4 and anti-PD1. C) Boxplot of %PDL1 staining and response.  
D) Model for how the opposing roles of IFN signaling in immune and tumor cells 
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Section 2.10 Discussion 
 
In this study, we describe how IFNG signaling in tumor cells antagonizes both T cell and 
innate immune responses. This is accomplished through an inhibitory feedback circuit 
orchestrated by tumor cells whereby IFNG from immune cells not only regulates its own 
inhibition but tightly controls adaptive and innate immunity (Figure 7G). Our current and 
previous findings suggest several main components to this IFNG circuit. First, we 
previously reported that persistent IFNG signaling can initiate epigenetic changes in 
cancer cells characterized by enhanced STAT1-associated open chromatin (Benci et al., 
2016) that includes loci for ISGs belonging to ISG.RS genes (unpublished data). Since 
resistance caused by persistent IFNG signaling can take several weeks to establish, these 
results suggest that the first component of the feedback circuit is the establishment of an 
epigenetic landscape in cancer cells that is permissive for enhanced ISG.RS expression. 
The second component is enforcing T cell exhaustion through high levels of PDL1 and 
likely other inhibitory ligands, which may include HVEM, LGALS9, and others (Benci et 
al., 2016). How the increase in these inhibitory ligands are mechanistically related to the 
epigenetic changes is currently unclear. Nonetheless, the end result is interactions 
between cancer and immune cells that favor an exhausted T cell state characterized by 
decreased IFNG and CTL function. The third component is inhibition of innate immunity 
by impeding NK/ILC1 effector function and differentiation. IFNG signaling in cancer cells 
not only increases PDL1 but decreases TRAILR2, which is the receptor for TRAIL 





 NK/ILC1 cells is antagonized. Additionally, the decreased production of IFNG by 
T cells further safeguards against innate immune killing by stalling NK/ILC1 recruitment 
and/or maturation. This may be at least partly due to diminished expression of CXCL9/10 
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from myeloid cells. Thus, IFNG signaling in cancer cells orchestrates feedback inhibition 
on multiple levels to limit both adaptive and innate immune function.  
By preventing tumor IFNG signaling, both adaptive and innate immune functions are 
unleashed (Figure 7G). However, the degree to which each of these effector arms 
contribute to response is context dependent. In tumors that are less reliant on IFNG for 
high MHC-I expression and antigen presentation (e.g., CT26 and TSA), blocking tumor 
IFNG signaling enables TEX to coordinate both CTL- and NK/ILC1-mediated responses. 
For tumors with low baseline MHC-I that are reliant on IFNG to elevate MHC-I expression 
(e.g., B16), a decrement in CTL killing is likely; however, the presence of innate immune 
killing can help to maintain overall response. For tumors such as Res 499 with poor 
neoantigens and low MHC-I, or for tumors that have lost B2M, compromised IFN-inducible 
MHC-I is likely inconsequential. Here, enhanced IFNG production by cross-primed TEX or 
possibly activated bystander T cells increases IFNG signaling in immune cells and 
maturation of NK/ILC1s. Ablating tumor IFNG signaling may particularly help activate 




 ILC1 cells by increasing tumor TRAILR2, 
decreasing PDL1, and/or altering other inhibitory pathways present on NK cells and/or 
ILC1s (Figure 2.3G). Thus, preventing tumor IFNG signaling enhances both adaptive and 
innate immune effector function but the magnitude that each contributes to response is 




 T cells are not able to effectively mediate direct cytolytic tumor killing, the 
ability of TEX to generate IFNG is important to promote NK/ILC1 function. Preventing tumor 
IFNG signaling both enhances CD8
+
 T cell abundance and drives them toward terminal 
exhaustion, a state characterized by high IFNG production compared to progenitor TEX. 
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Our studies also suggest that IFNG produced by cross-primed and/or activated bystander 
T cells might be sufficient to sustain NK/ILC1 maturation and NK/ILC1-dependent tumor 
killing. These findings have relevance for bystander T cells to common viruses and other 
non-tumor antigens that not only are abundant in human tumors (Simoni et al., 2018) but 
can be leveraged for immunotherapy (Rosato et al., 2019). One reason why antigen-
restriction may not be required is because the stimulatory effects of IFNG on NK/ILC1s 
are indirect. IFNG from CD8
+
 T cells appear to increase IFNG.GS expression 
predominantly in DC and myeloid cells, and IFNG.GS genes such as Cxcl10 then 
influences intratumoral NK/ILC1 abundance. In melanoma patients, IFNG.GS is also 
highest in macrophages and positively correlates with the proportion of activated 
intratumoral NK cells (Benci et al., 2019). Thus, tumor-specific TEX or activated bystander 

















CHAPTER 3 - Delivery of Immunostimulatory RNA by CAR-T Cells Activates RNA 
Pattern Recognition Receptors and Endogenous Immunity to Overcome Tumor 
Resistance 
Section 3.1 – Introduction 
 
Cell therapies such as chimeric antigen receptor (CAR) T cells have generated remarkable 
outcomes in a small subset of liquid cancers. Unfortunately, these therapies remain 
ineffective in the majority of solid tumors. Among the factors that contribute to poor efficacy 
in solid tumors are poor expansion and persistence of transferred cells in the tumor 
microenvironment  (Martinez and Moon, 2019). However, even if CAR-T cells do 
successfully engage cancer cell targets, a fundamental limitation of singly-targeted 
adoptive cell therapies is the outgrowth of tumors arising from cells that have lost 
expression of CAR-specific antigen (Gardner et al., 2016; Sotillo et al., 2015). In contrast 
to adoptive cell therapy, immune checkpoint blockade (ICB) stimulates endogenous T 
cells of multiple specificities and/or activates innate immune cells to potentially yield a 
polyclonal anti-tumor response (Keskin et al., 2019; Wu et al., 2020). However, due to a 
low mutational burden and immunoediting in most cancers, the lack of strong neoantigens 
can make this endogenous T cell repertoire ill-equipped for effective tumor eradication. 
For both CAR-T cell and ICB therapy, expression of negative immunoregulatory genes 
such as PDL1 (Liu et al., 2016a) and production of suppressive cytokines like TGFB (Kloss 
et al., 2018; Tang et al., 2020) within the tumor microenvironment (TME) are additional 
barriers that impede immunotherapy response. Thus, strategies that simultaneously 
employ CAR-T cells, enhance endogenous T cell function, and counteract common 
suppressive mechanisms may offer effective approaches to improve solid tumor response. 
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Damage-associated and pathogen-associated molecular patterns act as ligands for 
pattern recognition receptors (PRRs) that signal tissue injury and/or pathogen invasion. 
The activation of PRRs can initiate an innate immune response that is a prerequisite for 
mounting successful adaptive immunity. RIG-I and MDA5 are cytoplasmic PRRs that 
typically recognize virus-encoded double stranded RNA (dsRNA) with a 5’-triphosphate. 
Upon activation, these PRRs aggregate with the MAVS signaling platform (Reikine et al., 
2014) to enhance production of interferon (IFN) and induce transcription of interferon 
stimulated genes (ISGs). Such innate immune signaling is particularly important for 
myeloid and/or dendritic cells (DCs) to effectively prime and/or activate T cells 
(Kandasamy et al., 2016; Sprokholt et al., 2017a). For example, viral RNA or synthetic 
mimetics such as poly I:C can promote anti-tumor T cell responses by improving co-
stimulation and antigen presentation in T cell/DCs interactions (Hammerich et al., 2019; 
Salmon et al., 2016). However, recent evidence demonstrates that endogenous nucleic 
acids can also serve as damage-associated molecular patterns (DAMPs) to activate 
PRRs. RN7SL1 (7SL) is a highly structured noncoding RNA that is present in all cell types 
and conserved from humans to bacteria (Denks et al., 2014). Under homeostatic 
conditions, 7SL functions as a molecular scaffold crucial for protein translation. In this role, 
it is decorated by a number of RNA binding proteins that shield it from recognition by 
cytosolic RNA sensors such as RIG-I and MDA5 (Halic and Beckmann, 2005). However, 
under pathological conditions, decreased interaction with RNA binding proteins enables 
7SL to become unshielded and secreted via extracellular vesicles (EVs) such as 
exosomes. Consequently, unshielded 7SL now mimics viral RNA to activate a RIG-I-
dependent inflammatory response in cancer cells and myeloid cells (Nabet et al., 2017). 
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Although DAMPs can activate PRRs in cancer cells and immune cells, the consequences 
of inducing a type I IFN (IFN-I) or type II IFN response in each cell type for mounting an 
effective anti-tumor immune response can be complex and even opposing. While PRR 
activation and IFN signaling in DCs can be immunostimulatory, PRR and IFN signaling in 
cancer cells can drive cancer progression and enhance immunosuppression that leads to 
immunotherapy resistance (Benci et al., 2016; Boelens et al., 2014; Liu et al., 2016b). The 
immunosuppressive effects of tumor-intrinsic activation of ISGs is thought to occur through 
multiple mechanisms that include induction of immune inhibitory genes and genes that 
influence immune-mediated tumor killing. Thus, directing PRR and IFN signals toward 
immune cells and away from cancer cells may improve cancer immunotherapy (Benci et 
al., 2019). 
In this study, we engineer CAR-T cells to deploy 7SL to selectively activate PRR signaling 
in immune cells as opposed to cancer cells. As a consequence, this enables CAR-T cells 
to productively activate myeloid and dendritic cells, recruit endogenous T cells, and 
generate effective immunity against solid tumors. 
 
Section 3.2 – Biasing PRR activation through 7SL RNA away from cancer cells 
improves immunotherapy response 
 
We produced in vitro transcribed 7SL and a control RNA with the same nucleotide 
composition as 7SL but scrambled in its sequence (Scr). Additionally, a ribozyme 
sequence was used to generate a uniform 3’ end.  The 7SL RNA has extensive RNA 
secondary structure, while the Scr RNA is predicted to lack widespread dsRNA regions 
(Nabet et al., 2017). Both RNAs have a 5’-triphosphate, which is a feature that promotes 
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recognition by RIG-I. Compared to cellular RNA, which is primarily comprised of ribosomal 
RNA with a 5’-monophosphate, transfection of 7SL into B16-F10 melanoma cells or 
human DCs induces ISGs such as MHC-I, PDL1, or CD86 (Fig. 3.1A and S3.1A-B). ISG 
induction also occurs after transfection with poly I:C, which served as a positive control, 
or with the Scr RNA. Interestingly, the ability of 7SL to stimulate ISGs is dependent on 
both RIG-I and MDA5. In contrast, Scr RNA and Poly I:C only require one PRR or the 
other. Thus, although 7SL and Scr RNA both induce ISGs, 7SL RNA utilizes and/or relies 
on both RIG-I and MDA5, indicating that its’ signaling requirements may be distinct. 
To determine the consequence of 7SL and Scr RNA recognition in vivo we implanted B16 
tumors into the flanks of wildtype mice and injected liposome-encapsulated RNA 
intratumorally. While cellular and Scr RNA have minimal effect compared to a liposome-
only control, intratumoral injection of 7SL enhances tumor growth and decreases survival 
in mice unable to mount a T cell-dependent adaptive immune response due to T cell 
depletion (Fig. 3.1B). These results are consistent with our previous findings 
demonstrating that the activation of RIG-I by 7SL in cancer cells can promote tumor growth 
and metastasis in an immunocompromised setting (Nabet et al., 2017). To determine the 
effect of 7SL when the immune system is intact and activated, mice were treated with 
immune checkpoint blockade using anti-PD1 plus anti-CTLA4 rather than CD8
+
 T cell 
depleting antibodies. In this context, intratumoral injection of 7SL improves ICB response, 
while Scr and cellular RNA continue to have minimal effect (Fig. 3.1C). Accordingly, 7SL 
RNA also augments infiltration of proliferating and activated T cells, as well as enhances 
the frequency of intratumoral DCs (Fig 3.1D-E, Fig S3.1D). Thus, these results suggest 
that although stimulation of cancer cell-intrinsic RIG-I can promote tumor growth, this 
deleterious effect can be offset by the ability of 7SL to also promote immune activation. 
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Considering that activating cancer cell-intrinsic RIG-I can have unfavorable effects on 
tumor growth, we reasoned that stimulation of cancer cell RIG-I by 7SL might also 
negatively impact immune function even in the presence of ICB. Indeed, when B16 
melanoma cells with RIG-I knockout are implanted into flanks of mice and then treated 
with intratumoral 7SL RNA plus ICB, tumor response is improved compared to control 
wildtype B16 tumors (Fig 3.1F). In contrast, treatment with ICB alone does not favor 
response in RIG-I knockout tumors, suggesting that cancer cell RIG-I does not impact 
immunotherapy response in the absence of stimulatory RNA. In total, these results 
suggest that although 7SL can enhance immunotherapy, RIG-I activation in cancer cells 
can contribute to suboptimal response. Thus, strategies that bias delivery of 7SL away 







Figure 3.1. Localization of 7SL signaling dictates pro-tumor and pro-immune 
outcomes. A) B16-F10 cells of indicated genotypes were stimulated by transfection 
with in vitro transcribed 7SL RNA. 48 hours later, MHC-I levels were assessed by flow 
cytometry. B) C57BL/6 mice were treated with CD4 and CD8 depleting antibodies and 
then injected subcutaneously with B16-F10 tumors. Mice were then treated with 
indicated RNAs at days 5, 8, and 11. Tumors were monitored for growth until sacrifice 
criteria was reached. C) Mice were implanted with tumors as in B) and treated with 
RNA at days 5, 8, and 11 and anti-PD1 + anti-CTLA4 at days 8, 11, and 14. Tumors 
were again monitored for growth until sacrifice criteria was reached. D) C57BL/6 mice 
were implanted with B16-F10 tumors s.c. and then treated with indicated RNA at days 
5, 8, and 11. Tumors were harvested at day 15 and T cells were assessed for 
Granzyme B expression by flow cytometry. E) Frequency of intratumoral T cells 
expressing Ki67, Granzyme B, and CD69 as well as DC infiltration after treatment with 
indicated RNAs. F) Mice were implanted with indicated genotypes of B16 tumors and 
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Supplemental Figure 3.1. 7SL stimulates immune activation in vitro and in vivo. 
A) B16-F10 cells of indicated genotypes were stimulated by transfection with indicated 
RNAs. 48 hours later, PDL1 levels were assessed by flow cytometry. B) Healthy donor 
human PBMCs were stimulated with indicated in vitro transcribed RNA and CD86 
expression on DCs was analyzed 48 hours later. C) C57BL/6 mice were implanted with 
B16-F10 tumors s.c. and treated with indicated RNAs at days 5, 8, and 11. Survival is 
shown. D) Mice were treated as in C) and tumors were harvested at day 15 to perform 
flow cytometry. Expression of Ki67 in T cells is shown. E) Gating strategy to identify 




Section 3.3 – CAR-T Cells Can Preferentially Deliver 7SL RNA to Immune Cells Via 
Extracellular Vesicles 
 
In order to devise an approach to deliver 7SL RNA to tumors that biases uptake by immune 
cells instead of cancer cells, we investigated the potential for using CAR-T cells. We 
surmised that CAR-T cells not only can be engineered with these properties but doing so 
could arm CAR-T cells with unique functions. To test this hypothesis, we designed a base 
syngeneic CAR-T cell system in which murine T cells are transduced with a human 
CD19BBz CAR construct (Fig. 3.2A), and B16-F10 melanoma cells expressing human 
CD19 (B16-h19) are used as a solid tumor model (Fig. 3.2B). We then incorporated a U6 
promoter downstream of the CAR sequence to transcribe a 5’-triphosphate RNA of interest 
(Fig 3.2A). Here, 19BBz is combined with either human RN7SL1 RNA (19BBz-7SL), which 
only differs from the murine sequence at bases 18-20, or a scrambled control RNA 
(19BBz-Scr). Transduction of primary mouse T cells with either chimeric construct reveals 
that surface expression of the CAR is comparable (Fig. S3.2A) and both human 7SL and 
Scr RNA are constitutively detected (Fig. S3.2B). 
Since our previous work demonstrated that 7SL is transferred between different 
cell types in the TME through exosomes (Nabet et al., 2017), we reasoned that CAR-T 
cells might also export 7SL through extracellular vesicles (EVs) that can then be 
transferred to immune cells in the tumor. Indeed, 7SL RNA was detected in purified EVs 
from CAR-T cells using species-specific primers, as was the Scr RNA (Fig 3.2C). To 
determine if RNA contained in CAR-T cell EVs can be transferred to other cells in the 
TME, we utilized a fluorescent RNA-specific dye (SytoRNA Select) to label the RNA of 
congenically marked CD45.1
+
 CAR-T cells prior to transfer into CD45.2
+
 mice bearing 
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B16-h19 tumors. Indeed, a significant fraction of endogenous CD45.2
+
 immune cells, 
including myeloid cells, DCs, and endogenous T cells, are labeled with the SytoRNA dye 
indicating transfer from CAR-T cells (Fig. 3.2D). Consistent with EV-mediated delivery, 
transfer of CAR-T cell RNA is diminished in all immune populations examined after 
inhibiting EV secretion with GW4869, a neutral sphingomyelinase inhibitor known for 
limiting exosomal production (Trajkovic et al., 2008). To verify that 7SL or Scr RNA is 
among the RNA transferred from 19BBz-7SL or 19BBz-Scr CAR-T cells to endogenous 




 endogenous immune cells from B16-h19 
tumors and performed qRT-PCR for 7SL and Scr RNAs. Both 7SL and Scr RNA are 
detected in endogenous immune cells (Fig. 3.2E). Moreover, uptake of RNA from 19BBz-
7SL CAR-T cells in DCs and macrophages led to upregulation of the activation marker 
CD86 in these populations (Fig S3.2E). Finally, RNA from CAR-T cells is preferentially 
taken-up by CD45.2
+
 immune cells compared to cancer cells as measured by flow 
cytometry in individual tumors (Fig. 3.2G). In total, these results suggest that CAR-T cells 
can be used to preferentially transfer stimulatory RNAs such as 7SL to endogenous 






Figure 3.2. CAR-T cells localize therapeutic RNA delivery to immune cells over 
cancer cells. A) Construct design for 19BBz-7SL and 19BBz-Scr CAR-T cells. B) B16-
F10 cells were stably transduced to express the human CD19 antigen, stable 
expression shown by flow cytometry. C) EVs were purified from CAR-T cell culture 
media by ultracentrifugation. qPCR for indicated RNAs was performed on purified RNA. 
D) B16-h19 tumors were injected i.t. with SytoRNA-labeled CD45.1+ CAR-T cells at 
day 14. 24 hours later tumors were harvested and CAR-T derived RNA was observed 
by flow cytometry. E) RNA transfer in indicated populations was measured after pre-
treatment of CAR-T cells with exosome inhibitor GW4869 (NSMi) or DMSO. F) CD45.2+ 
immune cells positive for SytoRNA dye were sorted and cellular RNA was isolated. 
qPCR was then performed for RNAs of interest. G) The frequency of CAR-T RNA-
labeled 45.2
+
 immune cells and 45.2
-
 tumor cells was quantified by flow cytometry in 
individual tumors. Fold change from equal transfer is shown.  
7SL Scr












































Cd45.2 Myeloid DC T Cell






























0 10 20 30 40 50
















5’ LTR 19BBz TTTTTTTTTT U6 7SL/Scramble 3’ LTR



















CAR T Cells Cd45.2+ Immune Cells Myeloid Cells DC
SytoRNA
+/- NSMiSytoRNA Label

















Supplemental Figure 3.2. 19BBz-7SL CAR-T cells as a model for immune 
activation. A) Expression of the h19BBz CAR molecule was assessed on the surface 
of murine T cells transduced with h19BBz or h19BBz-7SL CAR constructs following T 
cell expansion. B) RNA was harvested from murine T cells transduced with the relevant 
CAR constructs. qPCR for RNAs of interest is shown. C) C57BL/6 mice were implanted 
with B16-h19 tumors and then treated with h19BBz or untransduced mCAR-T cells at 
days 5 and 12. Survival is shown. D) Mice were implanted with B16-h19 tumors and 
then injected i.t. with SytoRNA-labeled CAR-T cells. CD86 expression in RNA-labeled 
cells was quantified as a measure of activation in indicated populations. E) 
Representative plot of CD86 expression SytoRNA+ macrophages. 
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Section 3.4 – CAR-T Cell Delivery of 7SL to Solid Tumors Controls Tumor Growth 
 
In order to investigate if selective delivery of stimulatory RNA to immune cells is associated 
with improved CAR-T cell efficacy, we examined the survival of mice bearing B16-h19 
tumors after treatment with 19BBz-7SL, 19BBz-Scr, 19BBz, or untransduced (UTD) 
murine T cells. Although 19BBz-7SL CAR-T cells resulted in the best survival (Fig. 3.3A), 
this improvement is modest, since the delivery of 7SL to immune cells would be expected 
to primarily improve endogenous immune function. Therefore, to unveil the impact of 7SL 
RNA on the endogenous immune compartment, anti-CTLA4 was added to the CAR-T cell 
regimen. Under these conditions, delivery of 7SL by CAR-T cells markedly enhances 
tumor response compared to UTD or 19BBz-Scr CAR-T cells (Fig 3.3B), a result that is 
also observed in a Kras/p53 lung cancer model that is typically refractory to 
immunotherapy (Fig S3.3A). Although anti-CTLA4 also increases efficacy of 19BBz or 
19BBz-Scr CAR-T cells, this impact is modest compared to 19BBz-7SL CAR-T cells (Fig. 
3.3A-B), further suggesting that 7SL impacts the endogenous immune system. Indeed, 
the intratumoral delivery of 7SL by CAR-T cells is accompanied by greater infiltration of 
both CAR-T and endogenous immune cells even in the absence of ICB (Fig. 3.3C-D). 
Examination by single-cell RNA-sequencing (scRNA-seq) reveals that this increase in 
endogenous immune infiltration associated with 7SL primarily results from an increase in 
subsets of CD8
+
 T cells (Fig. 3.3E). By comparison, the main effect from intratumoral 
delivery of the Scr RNA is an altered immune composition characterized by enrichment of 
myeloid subsets. Thus, by engineering CAR-T cells to deploy 7SL selectively to immune 
cells, infiltration of both CAR-T and endogenous immune cells are enhanced. Upon 
addition of ICB, marked improvement in anti-tumor response ensues. 
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Immune infiltrate and tumor response after CAR-T cell therapy is improved with delivery 
of 7SL but not with Scr RNA, despite the fact that both RNAs induce ISGs after cellular 
transfection in vitro. To corroborate that differences between 7SL and Scr RNA are not 
simply due to gross differences in inducing ISGs in vivo, we examined ISG enrichment in 
CD45.2
+
 immune populations from B16-h19 tumors. Immune cells with the highest ISG 
expression include subsets of monocytes, macrophages, DCs, and a small population of 
T cells (Fig. 3.3F). These same immune cell populations can further induce ISGs after 
CAR-T cell delivery of 7SL or Scr RNA, with Scr RNA showing a slightly broader effect 
compared to 7SL (Fig. 3.3G). Notably, the expression of Rig-I (Ddx58) and Mda5 (Ifih1) 
are similar to each other and also follow a similar pattern to ISGs in general (Fig. 3.3H). 
Thus, these results suggest that the ability of 7SL to improve immune function after CAR-
T delivery compared to Scr RNA likely involves more complex mechanisms than activating 






Figure 3.3. 19BBz-7SL CAR-T cells improve endogenous immune activation and 
survival. A) Mice were implanted with B16-h19 tumors and then treated with CAR-T 
cells at days 5 and 12 or B) CAR-T cells plus ICB at days 8, 11, and 14. C) Mice were 
implanted with tumors and treated with indicated CAR-T cells at days 5 and 12. Tumors 
were harvested at day 15 and flow cytometry was performed, shown is frequency of 
live CD45.1
+
 CAR-T cells or D) CD45.2+ events. E) 45.2+ endogenous immune cells 
were sorted at d15 from B16-h19 tumors treated with indicated CAR-T cells and then 
subjected to single-cell RNA sequencing. Shown are identified clusters and density 
heat maps indicating frequency of labeled clusters. F) A metagene comprised of the 
Hallmark Type-I IFN geneset mapped onto the UMAP of all 45.2+ cells. G) Enrichment 
in individual clusters separated by CAR-T treatment group. Dark circles represent 
statistically significant enrichment as compared to enrichment of random genesets. H) 
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Supplemental Figure 3.3. 7SL- CAR-T cells improve KP lung tumor control. A) KP 
lung cancer cells were transduced to express hCD19 and treated with indicated mCAR-
T cells on day 5 and 12 plus anti-CTLA4 and anti-PD1. Tumor growth shown. 
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Section 3.5 – 7SL RNA delivered by CAR-T cells improves immunostimulatory 
properties of myeloid and DC subsets 
 
Since the ability to increase IFN signaling in immune cells does not obviously account for 
the different immunostimulatory effects of 7SL versus Scr RNA, we sought to more closely 
interrogate how each RNA differentially impacts immune cell properties. Given that Rig-I, 
Mda5, and ISGs show high expression in myeloid and DC subsets (Fig. 3.3H), we elected 
to first examine these innate immune cell types. Using Monocle and scRNA-seq data for 
CD45.2
+
 intratumoral immune cells, we inferred a differentiation trajectory and different 
cell states and then used genesets for various myeloid subsets to assign each state (Fig. 
3.4A-B). To define cells with immunosuppressive properties, genes for myeloid derived 
suppressor cells (MDSCs) and for Tgfb1 were evaluated (Alshetaiwi et al., 2020). As 
expected, delivery of either 7SL or Scr RNA by CAR-T cells increases ISGs across 
multiple myeloid states (Fig. 3.4C). However, delivery of the Scr but not 7SL RNA leads 
to higher frequencies of myeloid states enriched in MDSC genes, particularly the Mdsc.2 
state, which exhibits the greatest enrichment in MDSC genes that include Cd84 and Arg2 
(Fig. 3.4D). This was confirmed at a broad level using flow cytometry which revealed a 
higher frequency of Ly6C
+
 monocytes in 19BBz-Scr CAR-T treated tumors (Fig. S3.4A). 
Conversely, delivery of 7SL RNA decreases levels of Tgfb1, which is highly expressed in 
myeloid states that are largely distinct from the Mdsc.2 state. Together, these results 
suggest that although 7SL and Scr RNA both stimulate an IFN response, only delivery of 
7SL by CAR-T cells limits expression of MDSC genes and/or Tgfb1 across multiple 
myeloid cell types. 
To better define changes in DCs, DCs and monocytic DCs were re-clustered and 
assigned using genesets for established DC populations. Potential stimulatory properties 
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of each subset were also evaluated using several gene regulatory modules that change 
in response to DC activation (Zilionis et al., 2019). This includes a co-stimulatory module 
(Cd80, Cd86, Cd40, Relb, Cd83) and an inhibitory immunoregulatory module (Cd274, 
Pdcd1lg2, Cd200). Four major DC subsets including DC1 (characterized by Xcr1, Clec9a), 
DC2 (characterized by Itgam, Sirpa), DC3 (characterized by Ccr7), and plasmacytoid DC 
(pDC) (characterized by Siglech, Cd7, and Cd209a) were identified along with a fifth 
cluster primarily comprised of monocytic DCs (Fig. 3.4F-G). As with the myeloid states, 
delivery of either 7SL or Scr RNA by CAR-T cells increases ISG expression to varying 
degrees in some but not all subsets (Fig. 3.4H). However, only delivery of 7SL RNA 
increases the frequency of a pDC-like cluster (Fig. 3.4I), which we also confirmed by flow 
cytometry using CD209a as a representative marker (Fig. 3.4J, S3.4B). pDCs typically 
produce IFN-I in the context of viral infections (Webster et al., 2016), suggesting a similar 
viral-like response is elicited by intratumoral delivery of 7SL RNA. 7SL RNA leads to a 
more modest increase in frequency for the DC1 subset known to stimulate CD8
+
 T cell 
responses (Broz et al., 2014); however, this subset in particular exhibits reciprocal 
changes in key regulatory gene modules. Specifically, DC1 cells show an enrichment of 
the co-stimulatory module but a decrease in the inhibitory immunoregulatory module (Fig. 
3.4K). This favorable change in the ratio of costimulatory to inhibitory genes was confirmed 
using flow cytometry by showing an increase in DCs expressing CD86 in favor of PDL1 
(Fig. 3.4L, S3.4C).  
In total, these findings suggest that delivering an RNA that simply mounts an IFN 
response is not adequate to enable CAR-T cells to favorably enhance innate immune cells 
in the TME. Rather, the ability of 7SL RNA to improve CAR-T cell function is associated 
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with limiting the development of suppressive myeloid states and promoting DCs to adapt 






Figure 3.4. Single cell sequencing reveals improved DC and myeloid activation 
by 19BBz-7SL CAR-T cells. A) Non-DC myeloid clusters were isolated from the total 
45.2+ single cell dataset and subjected to pseudotime analysis using Monocle (top). 
Cluster identification was performed using previously defined genesets for myeloid 
populations (bottom). B) Cluster frequency is represented by brightness mapped onto 
the pseudotime trajectory, panels are split by CAR-T treatment. C) Hallmark IFN-I 
geneset mapped onto pseudotime trajectory. Enrichment in individual clusters shown, 
statistical significance determined by comparison to enrichment of random genesets. 
D) General MDSC geneset mapped onto pseudotime trajectory (left) and frequency of 
cells in MDSC clusters split by CAR-T treatment (right). E) TGFB expression mapped 
onto pseudotime trajectory. Enrichment in individual clusters shown, statistical 
significance indicated by outlined boxes. F) The DC cluster from total 45.2+ dataset 
was isolated and subjected to reclustering using Seurat (top). Cluster identification was 
performed using previously defined genesets for DCs (bottom). G) Cluster frequency 
is represented by brightness mapped onto the DC UMAP, panels are split by CAR-T 
treatment. H) Hallmark IFN-I geneset mapped onto DC UMAP. Enrichment in individual 
clusters shown, statistical significance indicated by outlined boxes. I) Frequency of DC 
clusters in different CAR-T treated tumors. J) CD209a expression mapped on DC 
UMAP and quantified by flow cytometry in CAR-T treated B16-h19 tumors. K) 
Expression of costimulatory or immune regulatory genes in DC clusters, significance 
indicated by outlined boxes. L) DCs from B16-h19 tumors were assessed for CD86 


















































































































































































































































































































































Supplemental Figure 3.4. Single-cell sequencing reveals altered myeloid 
differentiation patterns mediated by RNA CAR-T cells. A) Gating strategy to identify 
Ly6C+ monocytes from 45.2+ cells. Frequency of monocytes following treatment with 
indicated CAR-T cells is shown. B) Expression of CD209a on DCs from B16-h19 
tumors treated with indicated CAR-T cells. C) Representative expression of CD86 and 
PDL1 on DCs from B16-h19 tumors treated with indicated CAR-T cells. Ratio in Fig 




Section 3.6 – Delivery of 7SL RNA by CAR-T cells improves the function of 
endogenous CD8+ T cells 
 
Treatment with 19BBz-7SL CAR-T cells improves both the infiltration of endogenous T 
cells and stimulatory properties of DCs and myeloid cells in the tumor. To more deeply 
understand how these intratumoral T cells are affected, we extended our scRNA-seq 
analysis of CD45.2
+
 immune cells to non-naïve CD8
+
 T cells (Fig. 3.5A). Similar to the 
myeloid cell analysis, differentiation states and trajectories were inferred and genesets for 
CD8
+
 T cell subsets were used to assign the individual T cell states (Beltra et al., 2020). 
Using a set of core CD8
+
 T cell exhaustion genes, each state was first defined as 
exhausted or non-exhausted. Then, the exhausted and non-exhausted states were further 
refined using additional genesets for T cell subsets (Miller et al., 2019). This revealed that 
compared to tumors treated with 19BBz CAR-T cells, tumors treated with 19BBz-7SL 
CAR-T cells show an increase in effector-like T cells (TEFF) and in effector/memory-like T 
cells (TEM) that express Klrg1 and/or Tcf7 (Fig. 3.5B-D). Conversely, there is a decrease 
in Tox-expressing exhausted T cells (TEX), particularly exhausted T cells belonging to the 
progenitor 2 subset (TEX
prog2
). In comparison, delivery of Scr RNA results in effects that 
are intermediate between 19BBz and 19BB-7SL CAR-T cells. These changes in CD8
+
 T 
cell subsets are also corroborated by flow cytometry using ITGB7 as a marker for TEFF and 
TEM cells and TOX as a marker for TEX (Fig. 3.5C, 3.5E-F, S3.5A). Thus, these findings 
suggest that improved myeloid and DC function resulting from delivery of intratumoral 7SL 
fosters development of CD8
+
 T cells with effector/memory-like properties rather than 
features of T cell exhaustion. 
To more directly test the requirements for 7SL RNA stimulation of myeloid cells and DCs 
to promote improved CD8
+
 T cell function, we utilized mouse BMDCs stimulated with or 
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without RNA and assayed their capacity to activate OT-I CD8
+
 T cells against the 
ovalbumin (OVA, SIINFEKL) peptide (Fig. 3.5G, left). This revealed that stimulation of 
BMDCs with liposome-encapsulated 7SL RNA is sufficient to enhance proliferation of OT-
I T cells and their production of effector proteins such as GzmB and IFNG (Fig. 3.5G, 
right). A similar effect is also observed using EV RNA isolated from 19BBz-7SL CAR-T 
cell cultures (Fig. 3.5H). In contrast, the stimulatory effects of 7SL RNA are largely 
abrogated when BMDCs from MAVS knockout mice are used, consistent with 7SL 
activating RIG-I and/or MDA5 in myeloid/DC subsets (Fig. 3.5G, S3.5B). Indeed, 7SL 
stimulation of BMDCs also enhances production of IFNB and two assayed subtypes of 
IFNA (Fig. 3.5I) and blocking IFN-I receptor signaling with an anti-IFNAR antibody during 
T cell priming also interferes with T cell activation (Fig. 3.5J). Thus, these results suggest 
that when CAR-T cells deploy 7SL RNA, 7SL can directly elicit favorable changes in 
myeloid/DC subsets that help activate CD8
+




Figure 3.5. 7SL CAR-T cells enhance CD8+ T cell activation and differentiation 
through DC/T cell interactions. A) Non-naïve CD8+ T cells were isolated from the 
45.2+ single cell dataset and subjected to pseudotime analysis using Monocle. 
Trajectory (top) and cluster identification using previously defined genesets (bottom) is 
shown. B) Cluster frequency represented by brightness mapped onto psuedotime 
trajectory. C) Expression of relevant genes mapped onto pseudotime trajectory. D) 
Cluster frequency quantified from B16-h19 tumors treated with indicated CAR-T cells. 
E) Itgb7+ or F) Tox+ intratumoral CD8+ T cells were quantified by flow cytometry 
following treatment with indicated CAR-T cells. G) BMDCs from MAVS KO or matched 
C129/J mice were stimulated with in vitro transcribed 7SL or Scr RNA and co-cultured 
with OT-I T cells for 48 hours. Expression of Granzyme B, IFNG, and Ki67 was 
measured by flow cytometry. H) The same experiment was performed with EV RNA 
from 19BBz-7SL or control CAR-T cell culture media. Data normalized to 19BBz control 
EV RNA stimulation. I) BMDCs were stimulated with 7SL RNA and harvested 48 hours 
later to perform qPCR for Type I IFN transcripts. J) aIFNAR blocking antibody MAR1-
5A3 was added to BMDC cultures concurrently with OT-I T cells. Granzyme B 
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Supplemental Figure 3.5. 7SL enhances CD8+ T cell differentiation while limiting 
exhaustion. A) B16-h19 tumors treated with indicated CAR-T cells were harvested at 
day 15 and CD8
+
 T cells were analyzed for Itgb7 and Tox expression by flow cytometry. 
B) BMDCs from MAVS KO or matched C129/J mice were stimulated with in vitro 
transcribed RNAs and co-cultured with OT-I T cells for 48 hours. Representative flow 
cytometry plots for OT-I expression of Granzyme B are shown. 
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Section 3.7 – Type I IFN Production is Critical to the Activation of 19BBz-7SL CAR-
T Induced Anti-Tumor Immunity 
 
The ability of 7SL RNA to recruit and mitigate dysfunction of endogenous T cells 
suggests that 19BBz-7SL CAR-T cells might be armed with unique properties that can 
overcome resistance due to CAR antigen loss. To investigate this notion, we first 
determined if improved response with 19BBz-7SL CAR-T cells plus ICB requires 
endogenous T cells and DCs. Indeed, when Trac-/- mice are implanted with B16-h19 
tumors, the difference between 19BBz-7SL and 19BBz CAR-T cells is abrogated (Fig. 
3.6A), indicating that endogenous T cells are required for the therapeutic effect of 7SL. 
Next, we investigated the role of DCs, particularly DC1 cells that exhibit preferential 
expression of costimulatory versus inhibitory genes after 19BBz-7SL CAR-T cell 
treatment. For this, we used BATF3 knockout mice, which lack the DC1 population (Fig 
S3.6A). In the absence of DC1s, treating tumor-bearing Batf3-/- mice with 19BBz-7SL 
CAR-T cells increases the frequency of the DC2 subtype (Fig. 3.6B). This suggests that 
although infiltration of endogenous CD8
+
 T cells and CAR-T cells are diminished in Batf3-
/-
 mice (Fig. 3.6C-D), CAR-T cells can still infiltrate the tumor and exert effects on 
endogenous immune cells. Nonetheless, when mice are treated with CAR-T cells plus 
ICB, survival with 19BBz-7SL CAR-T cells is identical to 19BBz CAR-T cells (Fig. 3.6E) 
and mirrors the results from Trac-/- mice. This is further supported by a lack of endogenous 
T cell activation despite 7SL delivery in the absence of DC1 (Fig S3.6B). Thus, the specific 
benefit of intratumoral delivery of 7SL to enhance CAR-T cell responses requires both 
endogenous T cells and the DC1 subset of DCs. 
Our in vitro results suggest that 7SL activates RIG-I/MAVS and IFN-I signaling in 
DCs to facilitate T cell activation. To corroborate these findings, we utilized RIG-I knockout 
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mice. Although Ddx58-/- mice exhibit embryonic lethality and rare offspring are born at sub-
Mendelian ratios, we procured a small cohort and treated mice bearing B16-h19 tumors 
with 19BBz-7SL CAR-T cells plus ICB. In contrast to the effects from knocking out RIG-I 
in cancer cells (Fig. 3.1D), the absence of host RIG-I decreases survival, suggesting host 
RIG-I signaling is required for the therapeutic benefit of 7SL (Fig. 3.6F). Accordingly, anti-
IFNAR antibody similarly interferes with 19BBz-7SL CAR-T cell efficacy (Fig. 3.6G). This 
is accompanied by only a modest decrease in the proportion of endogenous intratumoral 
CD8
+
 T cells (Fig. 3.6H), but a failure by 7SL to enhance the frequency of the DC1 subset 
after 19BBz-7SL CAR-T cell therapy (Fig. 3.6I, Fig S3.6C). As a consequence, blocking 
IFN-I signaling also prevents the increase in ITGB7
+
 TEFF-like and TEM-like cells, GzmB 
expression, and proliferation typically observed after 19BBz-7SL CAR-T treatment (Fig 
3.6J-K, S3.6D-E). Together, these results corroborate that intratumoral delivery of 7SL by 






Figure 3.6. Type I IFN production is critical to the activation of 7SL-induced anti-
tumor immunity. A) Trac-/- mice were implanted with B16-h19 tumors and treated with 
indicated CAR-T cells at day 5 and 12 along with anti-CTLA4 antibodies. Survival is 
shown. B) B16-h19 tumors were harvested from Batf3-/- and WT C57BL/6 mice at day 
15 following CAR-T cell treatment. Frequency of cDC2, C) CD8+ T cells, and D) CAR-
T cells was assessed by flow cytometry. E) Batf3-/- mice were were implanted with B16-
h19 tumors and treated as in A). F) RIG-I KO or WT littermate controls were implanted 
with B16-h19 tumors and treated with CAR-7SL and anti-CTLA4 as in A). Survival is 
shown. G) Mice were implanted with B16-h19 tumors and treated with indicated CAR-
T cells concomitatnly with aIFNAR blocking antibody. Survival is shown. H) Tumors 
were harvested from mice treated with CAR-T cells + aIFNAR antibody at day 15 to 
assess CD8
+
 T cell frequency. I-K) Mice bearing B16-h19 tumors were treated with the 
indicated CAR-T cells with and without concomitant aIFNAR antibody treatment. 
Frequecy of I) cDC1, J) Itbg7+ CD8+ T cells and K) Granzyme B+ or Ki67+ T cells was 
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Supplemental Figure 3.6. Batf3+ DCs and Type I IFN contribute to 7SL-induced 
anti-tumor immunity. A) B16-h19 tumors were harvested from WT or Batf3-/- mice 
and analyzed for the presence of cDC1s. B) Endogenous CD8+ T cells in tumors from 
Batf3-/- mice treated with indicated CAR-T cells were assessed for expression of 
activation markers Granzyme B and Ki67. C) Frequency of DC infiltration was assessed 
in mice treated with CAR-T cells concomitantly with aIFNAR antibodies. D) 
Endogenous T cells from tumors in mice treated with indicated CAR-T cells were 
assessed for Granzyme B and Ki67 expression. E) Granzyme B expression in T cells 




Section 3.8 – Delivery of 7SL by CAR-T cells orchestrates endogenous immune 
activation to overcome resistance due to antigen loss 
 
TRP2 is an immunodominant B16-F10 melanoma self-antigen that can mediate 
tumor rejection (Bloom et al., 1997). To determine if endogenous immune activation by 
19BBz-7SL CAR-T cells can enhance the function of TRP2-reactive endogenous CD8
+
 T 
cells, we utilized a TRP2 tetramer (Fig S3.7A). As predicted, TRP2-specific CD8
+
 T cells 
express higher levels of GzmB and Ki67 in mice treated with 19BBz-7SL CAR-T cells 
compared to 19BBz or 19BBz-Scr CAR-T cells (Fig. 3.7A). Moreover, this increase was 
blocked by anti-IFNAR treatment (Fig. S3.7B). Given these findings, we reasoned that 
19BBz-7SL CAR-T cells might be less susceptible to CAR-T cell resistance arising from 
loss of CAR antigen. To simulate this common resistance mechanism, we implanted mice 
with a 1:1 mix of B16-h19 cells that express human CD19 with control B16 cells that lack 
human CD19 (Fig. 3.7B). While 19BBz and 19BBz-Scr CAR-T cells are largely ineffective, 
19BBz-7SL CAR-T cells eradicate these heterogenous tumors comparably to pure B16-
h19 tumors (Fig. 3.7C). Mice treated with 19BBz-7SL CAR-T cells that had a complete 
response were then rechallenged at day 80 with a pure B16 tumor lacking human CD19. 
Here, 80% (4 out of 5) mice remain tumor-free at 140+ days, consistent with the generation 
of endogenous effector-memory T cells against tumor antigens (Fig 3.7D). In total, these 
data demonstrate that arming CAR-T cells with the ability to deploy 7SL RNA results in 
the activation of endogenous innate immune cells and tumor-reactive effector-memory T 
cells. These new functions can make CAR-T cells less susceptible to resistance due to 






Figure 3.7. 19BBz-7SL CAR-T cells activate tumor-specific CD8+ T cells and 
eliminate heterogenous solid tumors. A) B16-h19 tumors were harvested from mice 
treated with indicated CAR-T cells at day 15. TRP-2 tetramer+ endogenous CD8
+
 T 
cells were evaluated for Granzyme B and Ki67 expression by flow cytometry. B) Model 
for heterogenous solid tumor CAR-T cell therapy. C) Mice were implanted with a 1:1 
mixture of B16-h19 and WT tumor cells and then treated with CAR-T cells and anti-
CTLA4. Survival is shown. D) 19BBz-7SL CAR-T treated mice from C) were 
rechallenged with WT B16-F10 tumor cells and survival was monitored. E) Proposed 
model for role of PRR signaling in solid tumors from both endogenous sources and 








































































































Supplemental Figure 3.7. Tumor-specific CD8+ T cell activation is dependent on 
Type I IFN. A) B16-h19 tumors were harvested at day 15 and stained with TRP2-
specific or Ova control TCR tetramer. B) TRP2-tetramer+ CD8+ T cells from B16-h19 
tumors were assessed for Granzyme B expression following CAR-T treatment in the 




Section 3.9 Discussion 
 
Here we present a novel cell therapy inspired by the discovery of a naturally 
occurring intratumoral PAMP.  Delivery of the immune-stimulatory RNA RN7SL1 
enhanced infiltration of both engineered and endogenous immune cells, and appears to 
bias inflammatory signaling to the intratumoral immune compartment. This improved 
endogenous T cell proliferation and cytotoxicity, and enhanced survival as a single therapy 
and or in combination with immune checkpoint inhibitors. This immune response was 
dependent on BATF3+ DCs and their ability to prime anti-tumor CD8
+
 T cell responses. 
These cells are able to take up CAR-T derived RNA and become activated. This may 
represent a novel priming signal in the TME that facilitates the initiation of anti-tumor 
immunity, and outlines a novel therapeutic modality for the delivery of immunostimulatory 
cues. 
A key insight of this paper and others is the importance of distinct cellular compartments 
in determining the outcome of inflammatory signaling with regard to pro-immune or pro-
tumor effects. In turn, this is a crucial determinant of survival outcomes in preclinical and 
clinical studies (Benci et al., 2019). Specifically, we see that in the absence of anti-tumor 
immunity, 7SL RNA promotes tumor growth by activating ISGs in tumor cells. In contrast, 
7SL RNA promotes response to therapy and improved survival when the immune system 
is primed using ICB. Combining these observations, response is most improved when 
tumor cells are unable to recognize 7SL through the genetic deletion of RIG-I and the 
immune system is additionally primed with ICB treatment. This suggests that inflammatory 
signaling promotes competing processes in distinct cellular compartments, and that 
targets for enhancing response to immune-based therapies should focus on non-
overlapping pathways between immune and cancer cells. For example, our data suggests 
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targeting a gene crucial to the activation of ISGs in cancer cells, but not in DCs, might bias 
inflammatory signaling strongly toward the immune compartment. Similarly, activation of 
pathways exclusive to immune cells such as some TLRs and RLRs (Dajon et al., 2017) 
may limit cancer cell-associated inflammation while activating anti-tumor immunity. 
One way to achieve this preferential signaling may be delivery of 
immunostimulatory cues by an engineered immune cell. We observe greater uptake of 
CAR-T RNA by endogenous immune cells than tumor cells in the TME, suggesting 
immune cells may preferentially interact with one another at sites such as tertiary lymphoid 
structures (Joshi et al., 2015), which in turn enhances local immune priming events. 
Intriguingly, CAR-T/DC interactions have been reported in the tumor draining lymph node 
(Ma et al., 2019), suggesting that these cell types readily interact and may form a crucial 
signaling axis for CAR-T delivered therapeutics such as those described here. Specifically, 
we describe a circuit in which CAR-T derived 7SL RNA drives enhanced Type I IFN 
signaling in myeloid/DC populations, which in turn drives the expansion of an effector-like 
CD8
+
 T cell cluster that is able to functionally improve control of solid tumors. This differs 
from the well-described differentiation into exhausted CD8
+
 T cells typically observed in 
solid tumors, which does not control tumor growth. This is somewhat surprising given 
previous reports suggesting that chronic Type I IFN signaling contributes to T cell 
exhaustion (Teijaro et al., 2013; Wilson et al., 2013), and again points to the complexity 
and context-dependent nature of inflammatory pathways in the TME.  Our results highlight 
the acquisition of an effector-like CD8
+
 T cell program and control of solid tumors; this is 
consistent with recent reports highlighting the increased efficacy of immunotherapy when 
T cells are diverted from the exhausted T cell fate (Chen et al., 2019; Lynn et al., 2019; 
Wei et al., 2019), and suggest a paradigm by which modulating soluble cues has the 
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potential to influence this process. Interestingly, in a model of acute viral infection IFN-I 
signaling is crucial for the acquisition of effector phenotype and cytolytic function (Wiesel 
et al., 2012). This further suggests that 7SL delivery may mimic an acute local viral 
infection which drives less chronic T cell differentiation and more effector like gene 
programs. This demonstrates that altering soluble cues involved in T cell priming may 
drive functionally different T cell fates in the TME, and shows a need for further research 
into the role for many of these cytokines in anti-tumor T cell responses. Finally, 19BBz-
7SL CAR-T cells are able to overcome antigen heterogeneity in a solid tumor model that 
is not possible with standard-of-care 19BBz CAR-T cells through this activation of 
endogenous CD8
+
 T cell responses. This type of epitope spreading represents a major 
goal for the CAR-T and immunotherapy fields, and provides a significant opportunity to 
expand these therapeutic modalities into larger patient populations. In total, this work 
underlines the importance of cellular compartmentalization of signaling in the TME and 












CHAPTER 4 – CONCLUSIONS AND FUTURE DIRECTIONS 
Section 4.1 – IFNG Signaling in ICB Responses 
 
In Chapter 2 we describe how IFNG signaling between immune cells and cancer cells 
orchestrates opposing functions to both impact and predict ICB response. In immune cells, 
IFNG signaling supports anti-tumor responses, while in cancer cells IFNG augments 
MHC-I expression. Opposing these immune stimulatory effects, IFNG signaling in tumor 
cells drives feedback inhibition by increasing multiple inhibitory pathways that include 
PDL1. As a consequence, these inhibitory pathways on cancer cells not only promote T 
cell exhaustion but also interfere with maturation of NK/ILC1s and protect against their 
cytotoxic effects. Thus, in tumors that are less reliant on IFN for MHC-I expression and 
antigen presentation, blocking tumor IFN-driven resistance can improve ICB response. 
For tumors with adequate neoantigens and high constitutive MHC-I, the improved function 
of TEX enables CTL-mediated anti-tumor responses. This is associated with immunological 
memory and can even result in profound spontaneous regression in the absence of ICB. 
For tumors with depleted neoantigens that are otherwise likely resistant to ICB, ablating 
tumor IFN signaling also improves TEX function. In this situation, loss of IFN-inducible 
MHC-I is less consequential for CTL function. Improved ICB response results from 
enhanced IFNG production by T cells that promotes intratumoral NK/ILC1 accumulation 
and maturation. This allows a PD1
+
 NK/ILC1-like subset to restore ICB response, an effect 
that is facilitated by inhibition of Tregs (Benci et al., 2019). Altogether, these results 
illustrate how IFNG operates between adaptive immune cells, innate immune cells, and 
cancer cells to coordinate immune stimulatory and inhibitory effects. When the inhibitory 
effects directed by tumor cells are targeted, this can unleash a feed-forward mechanism 
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coordinated by adaptive and innate cells with the potential to improve ICB response even 
in tumors with neoantigen or MHC-I deficiency. 
Biomarkers and multivariate models that can accurately predict clinical ICB 
response are an important step in effectively translating immunotherapies. TMB and 
IFNG-related genes such as PDL1 are undoubtedly important predictive features. High 
TMB and expression of IFNG-related genes both can positively associate with ICB 
response (Ayers et al., 2017; Rizvi et al., 2015), while genomic or copy number alterations 
within B2M and IFN pathway genes can portend resistance and relapse (Gao et al., 2016; 
Zaretsky et al., 2016). However, it is also clear that these features are imperfect. For 
example, patients with high PDL1 or IFNG-related genes frequently fail to respond, while 
patients with low TMB tumors or mutations in B2M or the IFN pathway may nonetheless 
benefit from ICB. Reasons for such incongruent observations include the failure of gene 
signatures to capture the inhibitory functions of IFN signaling, somatic IFN pathway 
variants that unknowingly interfere with these inhibitory functions, or the possibility that 
these inhibitory functions impact not only adaptive immunity but innate-immune killing as 
well. We find that incorporating the ISG.RS or IFN pathway variants into models that 
include TMB and IFNG-related genes improves the ability to predict clinical ICB response. 
Indeed, the biology uncovered by our experimental models reflects this improvement and 
the statistical associations that accompany it. Thus, although using ISGs from 
experimental models to predict clinical response requires further optimization, and the 
functional properties of tumor variants in IFN pathway genes requires experimental 
investigation, our results highlight the importance of biomarkers that capture opposing 
functions of IFN signaling. 
In addition to corroborating known immunostimulatory effects of IFNG, we describe 
additional properties of IFNG signaling between innate and adaptive immune cells that 
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can promote ICB response. Our work suggests that even if CD8
+
 T cells are not able to 
effectively mediate cytolytic anti-tumor killing due to poor neoantigens or defective antigen 
presentation, improving the ability of TEX to generate IFNG is important for the 
accumulation of intratumoral NK/ILC1s that can mediate tumor killing. Such a function of 
CD8
+
 T cells and TEX to support NK/ILC1s through IFNG are reminiscent of NKT cells 
(Godfrey et al., 2018). In fact, our studies suggest that CD8
+
 T cells required to generate 
IFNG need not be tumor-specific, as revealed by the ability of cross-primed bystander T 
cells to sustain NK/ILC1 accumulation and NK/ILC1-dependent tumor killing (Benci et al., 
2019). These findings may provide insight into a potential utility of bystander T cells to 
common viruses and other non-tumor antigens that are abundant in human tumors 
(Simoni et al., 2018). These stimulatory effects of IFNG on NK/ILC1s may be indirect. 
IFNG from CD8
+
 T cells may act on macrophages to drive NK/ILC1 expansion through 
cytokines such as IL-15 (Spits et al., 2016), enhance NK/ILC1 recruitment through CXCR3 
ligands (Pak-Wittel et al., 2013), or promote transdifferentiation of ILCs into ILC1s through 
cytokines like IL-12 (Nagasawa et al., 2017). Consistent with this notion, macrophages 
from melanoma patients express the IFNG.GS and positively correlate with the frequency 
of activated intratumoral NK cells (Benci et al., 2019). In mice, IFNG and the IFNG-
regulated CXCR3 ligand CXCL10 influences intratumoral NK/ILC1 accumulation and/or 
phenotype. Altogether, our findings suggest that IFNG can be harnessed by 
immunotherapy approaches to link tumor-specific TEX, bystander CD8
+
 T cells, and various 
types of innate immune cells against tumors differing in neoantigen status. 
In contrast to IFNG signaling in immune cells, IFNG signaling in tumor cells 
orchestrates resistance to ICB. We previously demonstrated that this tumor-driven 
feedback inhibition is initiated and maintained by chronic IFN signaling (Benci et al., 2016). 
This results in high levels of PDL1 and multiple other inhibitory receptor ligands (e.g., 
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TNFRSF14, LGAL9, etc.) that promotes the accumulation of TEX with markers of severe 
exhaustion. Besides the resulting TEX having poor cytolytic function, our data suggest that 
a consequence of diminished IFNG generated by severe exhaustion is the accumulation 
of immature CD11b
–/low
 NK/ILC1s, which themselves have decreased production of 
cytokines such as IFNG, low cytotoxic function, and is associated with human tumors with 
a poor prognosis (Chiossone et al., 2009; Jin et al., 2013). However, tumor IFNG can also 
directly interfere with NK/ILC1 function. One mechanism involves the same IFNG-
regulated inhibitory receptor ligands that promote TEX. In this study, we focus on PDL1 but 
do not rule out a role for the other ligands on tumor cells that are controlled by IFNG. A 
second mechanism involves IFNG decreasing expression of TRAILR2 on tumor cells. For 
tumors with poor or depleted neo-antigens, our findings suggest the need to first block 
PD1 on TEX to support NK/ILC1 maturation, and then to block PD1 on a NK/ILC1-llke 
subset to enable TRAIL-mediated killing. Whether targeting other IFN-regulated pathways 
or inhibitory receptor ligands on tumor cells or other cell types can further improve NK/ILC1 
function will be important to investigate (Benci et al., 2019). 





NK/ILC1 subset is currently unclear. Recent reports demonstrate that distinct ILC1-like 
cells have roles in cancer immunosurveillance (Dadi et al., 2016) or in cancer 
immunosuppression (Cortez et al., 2017; Gao et al., 2017). For the latter, an ILC1-like 
population that expresses multiple inhibitory receptors such as PD1, CTLA4, and LAG3, 
is less able to control tumor growth compared to conventional NK cells. In fact, evidence 
suggests that TGFB can promote immune suppression by driving the conversion of 
conventional NK cells into these ILC1-like counterparts. Although comparison between 
ILC populations between studies is a challenge, these TGFB-regulated ILC1-like cells may 




 NK/ILC1s in our study. If so, there may be a 
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precursor-product relationship between maturing CD11b
int





NK/ILC1s. Alternatively, these two populations might belong to separate lineages that are 
both dependent on a common cytokine like IL-15, or the ILC1-like cells may arise from the 
transdifferentiation of ILC2s and ILC3s under the influence of inflammatory cytokines. 
Regardless, by simultaneously increasing tumor TRAILR2 and decreasing expression of 
PDL1 and multiple other inhibitory ligands, ablating tumor IFNG signaling may help to 
reactivate otherwise poorly cytotoxic ILC1-like cells. Our findings also suggest that 
additionally interfering with Tregs is important to initiate killing by these NK/ILC1s, 
illustrating the diversity of the immunosuppressive mechanisms that need to be targeted 
(Benci et al., 2019). Thus, a growing understanding of how NK/ILC1 function can be 
restored may enable approaches that leverage innate immune killing of neoantigen poor 
tumors or tumors that have lost MHC-I expression. Observations that tumors with B2M 
deficiency can nonetheless respond to ICB highlight the potential of such strategies (Rizvi 
et al., 2018; Rodig et al., 2018). 
In this study we focus on how IFNG signaling between tumor cells, T cells, and 
innate immune cells orchestrates cooperative and opposing effects on anti-tumor immune 
responses. Besides IFNGR, inhibiting STAT1, IFNAR, or IFNGR and IFNAR in tumor cells 
also diminishes the expression of resistance-associated ISGs and in some cases result in 
greater anti-tumor responses than IFNGR knockout alone. Thus, how IFN-I contributes to 
IFN-driven resistance and differs from IFNG requires additional investigation, as does the 
roles of individual ISGs in ICB resistance. Such questions are particularly relevant given 
that mutations in human tumors potentially affecting either or both type I and II IFN 
pathways are observed. 
Interestingly, recent work has identified synthetically designed IFNG molecules 
that are able to uncouple functions of IFNG signaling in tumor cells (Mendoza et al., 2019). 
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A directed evolution approach generated IFNG molecules designed to bind IFNGR 
complexes with differing affinity for IFNGR1 and IFNGR2, in which increased affinity for 
IFNGR1, but decreased affinity for IFNGR2 resulted in decreased STAT1 signaling, and 
subsequently a bias towards MHC-I expression over PDL1 (and presumably other 
inhibitory receptors). This is of particular interest because our CRISPR design strategy 
utilized in Chapter 2 to create IFNGR
-/-
 cancer cell lines focused exclusively on the 
IFNGR2 gene body. While previous studies have demonstrated that loss of either IFNGR1 
or IFNGR2 abrogates productive signaling through the receptor complex (Bach et al., 
1996), a possibility remains that short-lived IFNGR1 homodimers are able to sense IFNG 
in the absence of IFNGR2, leading to similar immunogenic signaling resulting in MHC-I 
expression in the absence of PDL1. Future experiments will test this possibility through 
titrations of IFNG signaling in IFNGR2
-/-
 cell lines and additional deletion of IFNGR1. 
Regardless, therapeutic strategies such as the directed evolution of novel cytokine 
molecules represent an opportunity to uncouple pro- and anti- immune effects of IFN 
signaling in cancer cells. Further, a role for excessive IFNG signaling in T cell fratricide 
has been reported in the TME (Pai et al., 2019). Our work here does not consider that 
there may be a threshold at which increased IFNG signaling may become directly 
detrimental to anti-tumor T cells. It would be of additional interest to observe how altered 
IFNGR binding by synthetically designed IFNG molecules would affect the balance of 
fratricide and NK cell activation described in the work here. Finally, IFNGR deletion by 
CRISPR in adoptive cell therapy (ACT) approaches may also be an attractive strategy to 
limit this effect. 
Beyond IFNG, similar de novo design approaches have been taken with additional 
cytokines that function directly on T cells, such as IL-2 and IL-15 (Silva et al., 2019). These 
molecules have also been described to have pleiotropic effects in the TME, most notably 
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expansion of immune-suppressive Tregs (Busse et al., 2010), and systemic host toxicity 
(Schwartz et al., 2002) that compete with their function to activate CD8
+
 T cells. By 
modulating affinity for specific subunits of the common-gamma chain cytokine receptor, 
Silva et al. were able to specifically focus IL-2 and IL-15 signaling to the CD8
+
 T cell 
compartment through computational design of novel cytokines. Our work suggests that 
therapeutic approaches that target specific cellular compartments in this manner may be 
particularly efficacious in triggering anti-tumor immunity against a variety of tumor types. 
For example, identification of novel molecules capable of limiting ISGs specifically 
associated with ISG.RS might limit tumor ISG-resistance programs while leaving immune 
activation relatively unaffected. Alternatively, stimulating IFNG.GS genes specifically in 
immune cells might limit tumor resistance programs driven by the same genes. Additional 
work is needed to create such molecules in order to validate this hypothesis, but such a 
view might form the basis for novel targeted approaches to enhancing ICB responses in 
patients. 
 
Section 4.2 – CAR-T PAMP Delivery Enhances Endogenous Anti-Tumor Immunity 
 
Chapter 3 outlines the design of a novel cell therapy inspired by the discovery of a 
naturally occurring intratumoral PAMP.  Delivery of the immune-stimulatory RNA RN7SL1 
enhanced infiltration of engineered cells and activation of endogenous immune cells. This 
is achieved by localizing inflammatory PRR signaling to the intratumoral immune 
compartment. This strategy improved endogenous T cell proliferation and cytotoxicity, 
resulting in improved survival as a monotherapy and also in combination with previously 
reported ICB therapies. Enhanced response to therapy was dependent on the presence 
of DC1s and their ability to subsequently prime anti-tumor T cell responses. These cells 
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were able to uptake CAR-T derived RNA and become subsequently activated. This may 
represent an important priming signal in the TME that facilitates the initiation of anti-tumor 
immunity. 
Similar to results in Chapter 2, a key insight of this work is the relative contribution of 
inflammatory signaling in distinct cellular compartments to survival outcomes following 
ICB. Specifically, we see that in the absence of anti-tumor immunity, 7SL RNA activates 
ISGs in tumor cells and promotes tumor growth. In contrast, when the immune system is 
primed through the use of ICB, 7SL RNA promotes response to therapy and improved 
survival. Finally, response is most improved when tumor cells lack the ability to recognize 
7SL through deletion of RIG-I in combination with immune-stimulatory ICB. This suggests 
that PRR signaling promotes competing processes in different cellular compartments, and 
that the most promising targets for enhancing response to immune-based therapies 
should focus on non-overlapping pathways between immune and cancer cells.  
One way to achieve preferential PRR signaling in immune cells may be through delivery 
of a PAMP-like molecule by an engineered immune cell. We observe greater RNA uptake 
following CAR-T cell administration by endogenous immune cells in the TME as compared 
to tumor cells, suggesting that immune-based delivery may bias inflammatory signals to 
the endogenous immune compartment. This may be due to interactions at sites like lymph 
nodes or tertiary lymphoid structures (Joshi et al., 2015), enhancing local immune priming 
events. Intriguingly, CAR-T/DC interactions have been reported in the tumor draining 
lymph node (Ma et al., 2019), suggesting that these cell types readily interact. Our data 
does not consider lymph node interactions directly, but it is an intriguing possibility that 
CAR-T delivery of 7SL to DCs in the draining lymph node may drive functionally improved 
anti-tumor T cells through improved T cell priming. Specifically, we observe that CAR-T-
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derived 7SL RNA drives enhanced Type I IFN signaling and preferential expression of 
costimulatory molecules in intratumoral DCs, particularly DC1. This leads to the expansion 
of an effector-like CD8
+
 T cell population that drives enhanced solid tumor control. This 
differs from control tumors that are populated by more exhausted CD8
+
 T cells and are 
unable to control tumor growth. 
Interestingly, previous reports suggest that chronic Type I IFN signaling contributes to T 
cell exhaustion (Teijaro et al., 2013; Wilson et al., 2013).  This again highlights the 
complexity and context-dependent nature of these inflammatory pathways.  Our results 
show the acquisition of an effector-like CD8
+
 T cell transcriptional program, which is 
consistent with recent reports highlighting the increased efficacy of immunotherapy when 
T cells are diverted from the exhausted T cell fate (Chen et al., 2019; Lynn et al., 2019; 
Wei et al., 2019), and suggest a paradigm by which modulating soluble cues may control 
this process. Interestingly, during acute viral infection Type I IFN is crucial for the 
acquisition of effector phenotype and cytolytic function (Wiesel et al., 2012), further 
suggesting that 7SL delivery via CAR-T cell may be locally mimicking an acute viral 
infection and driving less chronic T cell differentiation. Thus, altering soluble cues involved 
in T cell priming may drive functionally different T cell fates in the TME. This highlights the 
need for further research into the role for many of these cytokines in anti-tumor T cell 
immunity.  
Our analysis has deeply explored the differentiation and activation of CD8
+
 T cells, but 
has largely ignored counterpart CD4
+
 T cells. However, IFN-I is a well-known CD4
+
 T cell 
polarization cytokine that drives Th1 differentiation (Havenar-Daughton et al., 2006). 
Indeed, Th1 CD4
+
 T cells have been implicated as a positive prognostic marker for 
response to ICB in murine models of disease as well as patients (Wei et al., 2017; Zhang 
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et al., 2018). Single cell analysis from 19BBz-7SL CAR-T treated tumors revealed a higher 
level of costimulatory molecule expression and Hallmark IFN-I signature in cDC2, which 
have been shown to activate CD4
+
 T cells (Binnewies et al., 2019). Additionally, CD4
+
 T 
cells from these tumors express higher levels of activation markers such as Ki67 (data not 
shown), suggesting that activation of multiple T cell compartments may be enhanced by 
7SL delivery. Further, our single cell dataset shows a modest decrease in Treg frequency 
following 19BBz-7SL CAR-T treatment, consistent with lower levels of TGFB, and further 
suggesting that CD4
+
 T cell differentiation may be influenced by 7SL delivery. In this case, 
we may be influencing naïve CD4
+
 T cells away from the Treg fate and toward Th1 
polarization through enhanced IFN-I signaling and decreased TGFB signaling (Chen et 




 T cell 
differentiation in response to 7SL delivery and TME modulation. 
While this work has focused on the inflammatory role of a structured RNA, we believe that 
these conclusions will extend to other naturally occurring PAMP/PRR combinations in the 
TME. Similar contradictions in the role of compartment-specific inflammation have been 
reached in the study of TLR3 (Liu et al., 2016b; Salmon et al., 2016), and IFNGR (Benci 
et al., 2016; Zaretsky et al., 2016) in recent years. Of particular interest, recent work has 
characterized active microbial communities within certain tumor types (Geller et al., 2017). 
The commensal microbiome is a well-known source of PAMP signaling in the 
gastrointestinal tract (Bach, 2018; Swiatczak and Cohen, 2015), and may well be a rich 
source for additional PAMP signaling through TLRs and inflammasomes within the TME 
of solid tumors. In addition, a role for endogenous PRR ligands such as DNA has been 
defined, but often in the activation of a single PRR (i.e. STING). This ignores any potential 
role for the simultaneous activation of multiple cooperating PRRs, such as the AIM2 
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inflammasome in the case of DNA. The effects of combinatorial PRR activation through 
delivery of single or multiple PAMPs will be a significant focus of this work moving forward. 
In addition to combinatorial effects, little research has been carried out on the relative 
quality of different PRR pathways in activating anti-tumor immunity. To this point, much 
work has demonstrated that different TLR, RLR, and inflammasome pathways can 
contribute to the activation of anti-tumor immunity (Segovia et al., 2020; Zitvogel et al., 
2015). However, none of this work has yet qualitatively compared the effects of one PRR 
against others. Similarly, a systematic approach for comparing immune agonists in this 
context has yet to be described. A major barrier in this case is defining an experimental 
system that is able to effectively answer this question. CRISPR screens have identified 
many regulators of tumor cell fitness (Manguso et al., 2017; Patel et al., 2017), but are 
limited to the identification of cell-intrinsic processes. Appropriate observation of systemic 
host immune interactions is best suited to in vivo models, but such approaches are 
generally not conducive to CRISPR screening because of scalability. Our work and others 
suggests that a potential solution to this qualitative question is the in vitro screening of 
DC/T cell interactions in the presence of various reported immunogenic molecules. This 
might include introduction of various PAMPs to BMDC cultures followed by RNA 
sequencing to identify IFN-I or IFNG.GS gene signatures that predict enhanced T cell 
priming and immune response in vivo. Alternatively, we might repurpose the BMDC/OT-I 
system outlined in Section 3.6 and utilize available GzmB-reporter OT-I T cells. In this 
case PAMPs would be added to BMDC/OT-I cultures and then reporter fluorescence could 
be assessed in a high-throughput manner to directly assay cytotoxic priming of CD8
+
 T 
cells. Chapter 2 suggests that we might then combine these assays with a similar screen 
on a panel of cancer cell lines in order to identify immunogenic molecules with greater 
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effects on immune priming than induction of ISG.RS in tumor cells. Many such approaches 
might be imagined, but answering this question remains a crucial barrier to translating 
these findings to patient benefit. 
In the clinic, PRR agonist therapeutics are currently given as systemic treatments or single 
local intratumoral injections (Hammerich et al., 2019). These strategies have yielded hints 
of positive response, but delivery via CAR-T cell as described in Chapter 3 offers several 
key advantages. First, the CAR construct itself imbues these cells with a synergistic 
therapeutic capability by their capacity to kill tumor cells. Further, as discussed in Section 
3.3, delivery via immune cell seems to bias our inflammatory stimulus toward a beneficial 
immune-focused PRR activation. This delivery also offers the ability to localize steady 
production of a therapeutic payload specifically to the TME, instead of systemic treatments 
that may result in undesirable toxicities (Hu et al., 2019; Sercombe et al., 2015). 
Additionally, this therapeutic framework could also be built to include safety switches such 
as inducible expression or suicide genes that have been previously reported (Lim and 
June, 2017). Finally, engineered T cells have shown an ability to infiltrate previously 
immune-sparse or “cold” tumors if targeted correctly (Posey et al., 2016). Our work 
suggests that the addition of immunogenic PAMPs to such therapies has significant 
potential to jump-start an endogenous anti-tumor immune reaction that would benefit a 
large portion of currently underserved cancer patients. 
Beyond an ability to stimulate endogenous immunity, we believe this cellular engineering 
architecture is also amenable to emerging technologies such as CRISPR genome editing, 
as well as more established therapeutic modalities such as RNAi. Currently, the standard 
method of delivery for these technologies in the clinic is through the use of liposomes. 
While significant progress has been made in enhancing the specificity and half-life of these 
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vesicles in the body, a majority are still taken up by off-target tissues (Riley et al., 2019). 
Approaches like integrin inclusion and membrane charging of synthetic vesicles 
(Deshpande et al., 2013), as well as direct exosome production (Dai et al., 2008) have 
improved these targeting capabilities somewhat, but liver and kidney tissue is still a 
primary sink for these vesicles in vivo (Sercombe et al., 2015). Indeed, the only currently 
approved RNAi therapy targets hATTR amyloidosis, a liver disease (Adams et al., 2018). 
Thus, strategies that improve the effective delivery of these therapies might greatly 
improve the reach of RNAi and other biologic therapeutics to a significantly wider range of 
diseases. 
 
Section 4.3 – Future Directions Understanding TME Inflammation and Broadening 
Therapeutic Strategies 
 
Our results in Chapter 3 suggest that inflammatory molecules like IFN-I play an important 
role in shaping the solid tumor TME. Here, we artificially mimic the presence of a naturally 
occurring PAMP, 7SL (Nabet et al., 2017); however, this is unlikely to be the only RNA of 
its kind capable of activating PRR signaling. Indeed, activation of IFN-I production may be 
attributed to many potential sources. Future experiments will focus on the identification of 
additional RNA PRR ligands and regulators of their expression. Previous studies indicate 
that de-repression of ERVs through the use of DNMT inhibitors may provoke upregulation 
of ISGs (Chiappinelli et al., 2015), and unpublished data in the Minn lab suggests that 
radiation may have a similar effect. Thus, ERVs (which are evolutionarily and structurally 
related to RN7SL1 (Okada, 1991) may represent an additional source of tumor-intrinsic 
inflammation. Our results in Section 3.2 suggest that non-therapeutic contexts in which 
these elements become de-repressed may represent an important cell-intrinsic resistance 
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mechanism for cancer cells and could represent a powerful prognostic marker. In order to 
test this hypothesis, we can interrogate a panel of ICB-resistant cell lines generated by 
the Minn Lab as well publicly available databases for presence of de-repressed ERV 
elements and correlations to resistance gene signatures like ISG.RS and others. 
Additionally, our data suggests that the activation of different PRRs may have important 
functional consequences. Specifically, 7SL RNA requires recognition by both RIG-I and 
MDA5 in order to stimulate ISG expression, while Scr control RNA required recognition by 
only RIG-I. Interestingly, this singular dependence led to significantly worse T cell priming 
than 7SL RNA in both in vitro and in vivo assays, albeit still better than non-immunogenic 
controls in many cases. This dual PRR dependence seems to be a unique property of the 
7SL RNA, as most reported RNA PRR ligands display specificity for a single receptor 
(Brisse and Ly, 2019). We predict that this dual-specificity arises from the specific 
combination of length, secondary structure, and 5’-triphosphate possessed by 7SL. In 
order to test this, we might denature our 7SL and Scr RNAs with and without phosphatase 
treatment specific to the 5’-triphosphate moiety. In this context, we would expect to retain 
characteristics similar to Scr RNA control when secondary structure is lost but 5’-
triphospahte is retained; namely, stimulatory capability dependent on RIG-I only. However, 
if secondary structure and 5’-triphosphate are lost, we might expect no immunogenic 
activity from either RNA. Given the size of 7SL RNA as compared to RIG-I or MDA5 
binding proteins, we would not expect these proteins to bind 7SL simultaneously. Thus, 
co-dependence of RIG-I and MDA5 for 7SL recognition might represent a forward-
feedback cycle in which both proteins are required in an unexpected way that should be 
further examined mechanistically. The identification of novel signaling modalities in these 
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well-characterized networks might uncover fundamental rules for the quality of certain 
RNA PAMPs as compared to others. 
Our work in Chapter 3 demonstrated the ability of CAR-T cells to deliver 7SL to immune 
cells in the TME via CD19-directed CAR that recognized a CD19-expressing melanoma. 
This is an artificial system, and demands that future experiments test 7SL delivery in the 
context of naturally occurring solid tumor antigens. Given that we envision this therapy 
moving forward in the context of heterogenous solid tumors, appropriate combinations 
might include mesothelin-targeted (i.e. M5) or Her2-targeted (i.e. 4D5) CARs in the context 
of lung cancer or breast cancer cell lines, respectively. We will carry out these experiments 
in both syngeneic models and NSG+ systems. This will be important in order to validate 
that human immune cells are also capable of RNA export and uptake demonstrated by 
murine cells in the work published here. Experiments could range from simple co-injection 
of PBMC with CAR-T cells in order to observe RNA transfer in the TME to more complex 
models such as BLT or MISTERG humanized mice that would allow measurement of 
“endogenous” immune infiltration and uptake, and potentially measurement of human cell 
efficacy if sufficiently reconstituted. 
Our results utilizing a heterogenous B16 tumor model also raise the possibility that 7SL 
delivery might expand the efficacy of previously characterized CAR molecules that have 
been shelved because of targeting concerns. This is an extension of the “on-target, off-
tumor” tradeoff outlined in Section 1.6. CARs designed to recognize and target tumor-
specific antigens such as TnMuc1 (Posey et al., 2016), and EGFRvIII (Morgan et al., 2012) 
are generally effective in preclinical models, but fail to induce durable tumor regression in 
patients because of incomplete antigen penetrance and target heterogeneity. For this 
reason, CARs with some off-tumor toxicity (i.e. mesothelin) have been prioritized with 
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careful dosing (Haas et al., 2019) and the hope of generating strong responses with 
manageable toxicity. Even so, these therapies are predicted to leave some antigen-
negative residual disease. Thus, delivery of an immunogenic RNA such as 7SL might 
enhance the safety of CAR-T therapy as whole by allowing use of safer CAR molecules 
that do not target healthy tissue. This would be complimented by the activation of 
endogenous T cell specificities that are generally not self-reactive. This presents a 
potentially breakthrough clinical benefit for this therapeutic approach. 
Our focus thus far has centered around the delivery of therapeutic RNA molecules. This 
is an exciting and novel use for engineered cell therapies, but we imagine a much broader 
therapeutic suite of molecules could be paired with this system. Taking inspiration from 
previous de novo protein design approaches (Hosseinzadeh et al., 2017; Mendoza et al., 
2019; Silva et al., 2019; Votteler et al., 2016), we predict that small bioactive peptides 
might serve as highly selective small molecule inhibitors or agonists in this framework. 
Future experiments will characterize an approach by which we can identify and optimize 
these molecules and test their efficacy in vivo when paired with CAR-T cell delivery. 
For example, DNA PRRs such as STING or TLR9 bind dinucleotide molecules (cGAMP 
or CpG) that cannot be encoded by DNA/RNA, and are therefore not able to be integrated 
with traditional cell engineering approaches. The upstream source for these ligands is 
free-floating DNA, which is also not compatible with viable engineered cells. For this 
reason, these pathways (and many others) are typically modulated through non-biologic 
small molecule agonists (Su et al., 2019). In order to target such a pathway, we propose 
that de novo design of a small peptide drug that is DNA-encodable could provide the same 
functionality and improve efficacy and tolerability through CAR-T cell delivery. To 
accomplish this, we might take a publicly available structure of STING/TLR9 in an active 
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conformation and utilize protein folding prediction algorithms to identify candidate peptide 
molecules that bind STING/TLR9 in this active conformation. Binding specificity might then 
be improved by applying principles of directed evolution until a small number of optimal 
candidates was reached. Downstream screening would validate candidates with biological 
activity, and we could then test delivery via CAR-T cell using the same systems described 
in Chapter 3. This idea is particularly attractive because it is theoretically applicable to any 
biological pathway of interest and could affect a variety of chronic disease conditions. 
For example, a number of papers in recent years have sought to identify pathways that 
may antagonize responses to immunotherapy, and would therefore make attractive 
targets for these de novo designed peptides (Benci et al., 2016; Ishizuka et al., 2019; 
Manguso et al., 2017). Alternatively, pathways that favor tumor cell death have been 
shown to enhance response to ICB (Vredevoogd et al., 2019; Wang et al., 2019; Zhang 
et al., 2020). Many of these cell death pathways converge on the SMAC family of proteins 
that translate extracellular cues into cell death or survival signals through SMAC/IAP 
interactions. SMAC mimetics that encourage cancer cell death have been designed and 
are well-tolerated, but lack efficacy (Jensen et al., 2020). Designing an inhibitor to this 
family of proteins might lower the threshold for immune-mediated cell death and enhance 
efficacy of CAR-T and/or ICB therapy. Similarly, synthetic-lethal screens have previously 
identified targeted molecules like PARP-inhibitors that are effective in small subsets of 
cancers but lack widespread adoption. Disruption of DNA repair pathways might greatly 
enhance antigenicity and immunogenic cell death, and could contribute strongly to 
enhanced endogenous immune activation (Harding et al., 2017) in combination with our 
CAR-T cell approach. We hope to identify several targets such as these in order to design 
and test the delivery of small peptide therapeutics in combination with CAR-T cell delivery 
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in the future. We believe this approach will increase local concentration of the relevant 
therapeutic through constant local production, while minimizing systemic distribution. 
At a more basic level, it is important that we understand how and why CAR-T cells seem 
to interact with immune cells more frequently than other cells in the TME. Potential 
explanations for this include preferential trafficking to tertiary lymphoid structures (Cabrita 
et al., 2020; Helmink et al., 2020; Petitprez et al., 2020) and draining lymph node 
interactions (Ma et al., 2019; Roberts et al., 2016), but detailed studies are needed to 
confirm this hypothesis. Single-cell spatial transcriptomic assays may provide an 
opportunity to ask these questions in a comprehensive way. Simultaneous observation of 
cellular localization in the TME combined with the ability to measure RNA transfer from 
engineered to endogenous cells would provide powerful evidence for the localization of 
these interactions. This might also inform outstanding questions about the ways in which 
cytokine distribution (Oyler-Yaniv et al., 2017) and inhibitory ligand distribution (Binnewies 
et al., 2018) within the TME affect anti-tumor immune responses. This might elucidate 
mechanisms by which NK cell maturation and recruitment highlighted in Chapter 2 are 
achieved by CD8
+
 T cells. For example, we might predict to find distinct 
microenvironments within the TME that are enriched for IFNG or TGFB signaling that 
dictate ILC1/NK cell differentiation. We believe these spatial factors may significantly 
contribute to the outcome of ICB and we hope to thoroughly address them in the future. 
In total, the work presented here outlines a framework for understanding the role of 
inflammatory signaling in distinct cellular compartments in the TME. This localization of 
signaling drives divergent outcomes following ICB, and is a crucial regulator of 
tumor/immune interactions. We find that tumor-intrinsic signaling drives treatment 
resistance and immune suppression, but localization of the same cues to the immune 
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compartment drives immune activation and downstream anti-tumor responses. Direct anti-
tumor responses include contributions by both T and NK cells depending on the antigenic 
context of the TME. We are able to leverage this finding through delivery of immunogenic 
7SL RNA by CAR-T cell to immune cells within the TME. This results in immune-focused 
RNA PRR signaling and activation of endogenous anti-tumor immunity. These responses 
engender clearance of heterogenous tumors: a longstanding goal in the field of 
immunotherapy. Thus, these findings underpin a novel paradigm for the delivery of 




CHAPTER 5 – METHODS 
Mice 
All animal experiments were performed according to protocols approved by the 
Institutional Animal Care and Use Committee of the University of Pennsylvania. Five to 
seven week old C57BL/6 (stock# 027) and BALB/c (stock# 28) mice were obtained from 
Charles River Laboratory. Five to seven week old female C57BL/6 (stock# 000664), 
Perforin knockout (C57BL/6-Prf1
tm1Sdz
/J; stock# 002407), IFNG knockout (B6.129SJ-
Ifng
tm1Ts
/J; stock # 002287), RAG1 knockout (B6.129S7-Rag1
tm1Mom
/J; stock# 002216), 
OT1 (C57BL/6-Tg(TcraTcrb)1100Mjb/J; stock# 003831), FoxP3-DTR (B6.129(Cg)-
Foxp3
tm3(DTR/GFP)Ayr
/J; stock# 016958); Batf3 KO (B6.129S(C)-Batf3
tm1Kmm
/J; 
stock#013755), TCRa KO (B6.129S2-Tcra
tm1Mom
/J; stock#002116), MAVS KO (B6.129-
Mavs
tm1Zjc





were ordered from Jackson Laboratory (Bar Harbor, ME). Female mice between the 
ages of 5-9 weeks were maintained under specific pathogen free conditions in order to be 
utilized in these experiments. 
 
Cell Lines 
B16-F10 melanoma cells (CRL-6457, male), TSA breast cancer cells (CVCL-F736, 
female), and resistant sublines were derived and cultured as previously described 
(Twyman-Saint Victor et al., 2015). CT26 colorectal cancer cell lines were purchased from 
ATCC and similarly cultured (CRL-2638, gender unknown). 
 
CRISPR gene targeting 
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Gene targeting by CRISPR/Cas9 was accomplished by co-transfection of a Cas9 plasmid 
(Addgene, 41815), the guide sequence (selected using ZiFit Targeter) cloned into the 
gBlock plasmid, and a plasmid with the puromycin selection marker. Successful targeting 
of the gene(s) of interest was determined by treating cells with and without 100 ng/mL of 
IFNG (PeproTech), 1000 units/mL IFN-beta (PBL Assay Science), or both depending on 
the target gene, and examining PDL1, B2M, or TRAILR2 surface expression by flow 
cytometry. Knockout cells were sorted from a bulk knockout population using 
Fluorescence Activated Cell Sorting (FACS) on the Aria (BD) or FACSJazz (BD) to 
maintain the diversity of the parent cells. The gene block contains 20 bp target size (N), 
















In vivo mouse studies 
Tumor injection and treatment schedule were done as previously described(Twyman-
Saint Victor et al., 2015). In Chapter 2 studies, both flanks were implanted, in Chapter 3 
studies a single flank tumor was utilized. Blocking antibodies were given on days 5, 8, and 
11 unless otherwise specified. Anti-CD8, anti-NK1.1., and anti-Asialo-GM1 were given on 
days -2, 0, 4, 8, 12, and 16. Antibodies against CTLA4 (9H10), PDL1 (10F.9G2), or PD1 
(RMP1-14) were all administered intraperitoneally at 200 ug/dose. In certain experiments, 
a single flank tumor was irradiated on day 8 utilizing a targeted SAARP machine. Isotype 
controls were used to confirm the lack of non-specific effects and a similar response and 
survival to untreated mice.  
 
Analysis of tumor growth, survival, and group differences 
Tumor volumes were determined by caliper measurements. Differences in survival were 
determined for each group by the Kaplan-Meier method and the overall p-value was 
calculated by the log-rank test using the survival R package. For mouse studies, an event 
was defined as death or when tumor burden reached a pre-specified size to minimize 
morbidity. Using the MASS R package, a mixed effect generalized linear model with 
lognormal distribution for tumor volume data was used to determine differences in growth 
curves. The significance of all two-way comparisons was determined by a two-sample 
two-tailed t-test, or by a one-tailed t-test when appropriate. For non-parametric data, a 




Single Cell Sequencing Preparation 
Tumors were harvested and viable CD45.2
+
 cells were FACS sorted on an Aria II. Single-
cell emulsions were obtained using the 10x Genomics Controller and the v2 Library and 
Gel Bead kit (10X Genomics) for data in Chapter 2, or v3 kit for data in chapter 3. RNA-
sequencing libraries were prepared as instructed by the 10x 3’ kit protocol. Resulting 




Tumors were harvested at day 13-15 post tumor implantation. Single-cell suspensions 
were prepared and red blood cells were lysed using ACK Lysis Buffer (Life Technologies). 
For in vitro cell lines, untreated or sub-confluent cells treated for 16 hours with 100 ng/mL 
of IFNG (PeproTech) were harvested and single-cell suspensions prepared. Similarly, 100 
ng/mL in vitro transcribed RNA formulated with Opti-Mem media and RNAiMax reagent 
were used to treat cell lines or healthy donor PBMCs and then stain for ISGs in some 
experiments. Live/dead cell discrimination was performed using Live/Dead Fixable Aqua 
Dead Cell Stain Kit (Life Technologies). Cell surface staining was done for 30 min at 4 
degrees. Intracellular staining was done using a fixation/permeabilization kit 
(eBioscience). Data acquisition was done using an LSR II (BD) or FACSCalibur (BD) and 
analysis was performed using FlowJo (TreeStar) or the flowCore package in the R 
language and environment for statistical computing. For high-dimensional flow cytometry, 
a FACSymphony (BD) was used for data acquisition and data analysis was done using 
the cytofkit R package and a custom analysis pipeline described in Quantification and 
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Statistical Analysis. Fluorophore-labeled antibodies were purchased from Biolegend, 
eBioscience, and BD. 
 
Intratumoral cytokine assay 
Approximately 200 ug of tumor was harvested, weighed, and placed in complete RPMI 
media for 4 hours at 37 degrees. The media was then harvested, spun to remove any 
remaining cells, and analyzed for cytokine expression (Luminex) according to the 
manufacturer’s instructions.  Resulting cytokine levels were then divided by the initial 
tumor weight for each sample.   
 
In vivo cytokine rescue studies 
All mice were pre-treated with anti-CD8 Two days before tumor injection. Either 1 ug IFNG 
or 100 ng CXCL10 was mixed in the PBS/tumor cell suspension prior to injection of the 
tumor. Mice then continued receiving 500-1000 ng IFNG or 100 ng CXCL10 
intra/peritumorally every 3 days post-tumor implantation.  For flow cytometry experiments, 
mice were harvested at day 13 to examine the effects of cytokine addback on immune 
recruitment in the absence of CD8
+
 T cells.  For survival experiments, intra/peritumoral 
injections continued every 3 days for the remainder of the experiment.    
 
OT1 mice studies 
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Transgenic OT1 mice or littermate wild type mice were implanted with tumors using Res 
499 cells with IFNGR and B2M knockout. Groups receiving Ova peptide had 50 ng of 
peptide mixed into the suspension prior to tumor injection and continued to receive 
intra/peritumoral injections on days 3, 6, 9, and 12. For flow cytometry experiments, mice 
were harvested on day 13.  
 
Murine chimeric antigen receptor T cells 
B16-F10, Res 499, or KP tumor cells were transduced with pCLPs-hCD19 lentivirus to 
express a truncated human CD19 antigen that is unable to drive intracellular signaling. 
Cells were double sorted for stable expression. 5x10
4
 tumor cells in log phase growth were 
implanted into flanks of B6 mice. Murine T cells were stimulated with CD3/CD28 
Dynabeads (Invitrogen) for 24 hours and then transduced with pMSGV-h19BBz, pMSGV 
h19BBz-7SL, or pMSGV h19BBz-Scramble retrovirus. At 48 hours after transduction, 
CAR-expressing T cells were quantified and 2-5x10
6
 CAR-expressing T cells were 
injected i.v. in mice bearing B16-, KP-, or Res499-hCD19 tumors 5 and 12 days after 
tumor implantation. Controls were either mock PBS-injected or control stimulated CAR-T 
cells, which gave comparable results. Where indicated, checkpoint blockade was 
administered on day 8, 11, and 14 when combined with CAR-T administration. 
 
In vivo RNA administration 
Mice were implanted with 5 x 10
4 
B16-F10 tumor cells and injected with 200 ng of indicated 
RNA peritumorally on days 5, 8, and 11. RNA was encapsulated in an emulsion of 
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RNAiMax reagent and FBS-Free Opti-MEM Media. For flow cytometry experiments, mice 
were harvested at day 15 to examine the effects of RNA administration on immune 





 (2.43) T cells 2 days before tumor injection, and were continually 
administered depleting antibodies every 4 days following. When combined with ICB, ICB 
antibodies (9H10, RMP1-14) were administered at day 8, 11, and 14. 
 
Extracellular Vesicle Purification 
T cells were expanded in culture as described above and harvested by centrifugation at 
2,000 rpm on day 4. Cell-free media was then spun again at 4,000 rpm for 10 minutes and 
subsequently filtered through a .2 uM filter. Vesicles were then obtained by centrifugation 
at 100,000 x g for 2.5 hours. RNA was purified from vesicles using Qiagen RNAEasy kit, 
and used for qPCR of transcripts of interest or BMDC stimulation. 
 
CAR-T RNA Labeling Experiments 
T cells were expanded as above and transduced with retroviral constructs as specified. 
Immediately prior to injection, cells were incubated with 500 nM solution of SytoRNA 
Select dye in PBS at 37 C for 30 min. Cells were washed three times to remove unbound 
dye, and then resuspended in 50 uL PBS for intratumoral injection. Tumors were 
harvested 24 hours later, and flow cytometry was performed to observe RNA fluorescence 
in various populations. In indicated experiments, cells were treated with 20 ug/mL of NSMi 
GW4869 or DMSO 24 hours prior to T cell harvest and injection. For qPCR experiments, 
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45.2+ endogenous immune cells that were labeled with SytoRNA dye derived from CAR-




BMDC of indicated genotypes were prepared by flushing bone marrow from mouse 
hindlimbs and plating 10
5
 cells/mL in RPMI media + 10% FBS and 30 ng/mL of GM-CSF. 
Media was changed at day 4 of culture while retaining non-adherent cells. BMDC were 
stimulated with 100 ng/mL of IVT RNA or 50 ng/mL of EV-RNA at day 4. RNA was 
prepared using serum-free OptiMEM media and RNAiMax reagent. On day 6, BMDC were 
harvested and loaded with 1 ug/mL SIINFEKL Ova peptide in serum-free PBS at 37 C for 
2 hours. BMDC were then washed three times to remove excess peptide and residual 
RNA and were resuspended in RPMI + 10% FBS. OT-I T cells were harvested from 
spleens of OT-I mice by CD8
+
 T cell enrichment and then cultured with peptide-loaded 
BMDC at a 1:1 ratio in 12 well plates. In indicated experiments, aIFNAR blocking antibody 
MAR1-5A3 was added to cultures at the time of T cell co-culture to block Signal 3 priming. 
 
qRT-PCR Gene Expression 
Relative gene expression levels after qRT-PCR were defined using either ΔCt or the ΔΔCt 
method and normalizing to GAPDH (cellular RNA) or 18s (EV RNA). Human-specific 7SL 
primers were designed to target a 3 bp difference in the mouse and human 7s1 and 7SL 

































IFNA primers identified by (Li and Sherry, 2010) 
 
In Vivo aIFNAR Blocking Experiments 
C57BL/6 mice were implanted with 5x10
4
 B16-hCD19 tumor cells. 24 hours prior to CAR-
T treatment, mice were injected with 200 ug of aIFNAR blocking antibody MAR1-5A3 or 
PBS control intraperitoneally. Additional injections were administered every 4 days until 
mice reached experimental endpoints. For flow cytometry experiments, mice were 





B16 Memory Rechallenge 
C57BL/6 mice were implanted with 5x10
4
 tumor cells mixed at a 1:1 ratio of B16-h19 and 
B16-F10 WT cells. Mice were then treated with CAR-T + ICB regimen as described above. 
On day 80, mice that had achieved complete responses via treatment with 19BBz-7SL 
CAR-T cells were challenged with 5x10
4
 B16-F10 WT tumor cells and tumor relapse was 
monitored. Mice were sacrificed at endpoints described above. 
 
Analysis of genomic features from clinical melanoma samples 
Processed bulk RNA-seq data from two different cohorts of melanoma patients treated 
with anti-PD1 (Hugo et al., 2017; Riaz et al., 2017) were downloaded from the GEO. 
CIBERSORT (Newman et al., 2015) was used to infer relative frequencies of immune cells 
in the tumor. For immune cell types with values for both resting and activated states, the 
values for the resting state were subtracted from values for the activated state. To 
calculate metagenes, gene expression data were centered and scaled using the sample 
mean and standard deviation, respectively. Then, the average expression of the genes in 
each gene set was calculated for each sample to give the metagene value. For tumor 
mutational burden, the provided values were log10 transformed. 
 
Single-cell RNA-sequencing analysis 
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For single-cell immune cell data from mouse tumors using the 10X Genomics platform, 
data were first processed using the Cell Ranger pipeline (10X Genomics). This included 
demultiplexing BCL files into FASTQ, performing alignment with STAR, UMI counting, and 
aggregating replicates of the same condition. Cells that had fewer than 500 genes 
detected, over 10% mitochondrial content, or over 3.5 times the median UMI count were 
removed. Genes expressed in less than 1% of cells were also removed. After these QC 
steps, UMI counts were imputed with SAVER (Huang et al., 2018). Seurat was then used 
to normalize data to sequencing depth using a LogNormalize implementation, and 
mitochondrial contamination and cell cycle effects were regressed out. Clustering was 
performed using Seurat’s graph-based clustering approach and visualized with tSNE or 
UMAP. Clusters were classified using a collection of manually curated immune marker 
genes (Chapter 2), or previously published genesets corresponding to known immune 
populations (Alshetaiwi et al., 2020; Beltra et al., 2020; Zilionis et al., 2019) (Chapter 3). 
Pseudotime analysis was performed using the Monocle package in R. Unsupervised 
analysis specified a seed population of cells and subsequent cell “states” along the 
pseudotime trajectory based on differentially expressed genes derived from comparisons 
between Seurat-identified clusters. States were then matched to known immune 
populations by reference genesets in the same manner as Seurat-identified clusters. 
Metagene values for IFNG.GS and Hallmark IFN-I geneset were determined similarly to 
the clinical analysis. The average scaled values for Mki67 and Top2a, and the average 
scaled values for Cxcl9 and Cxcl10 were used to calculate the proliferation and Cxcl9/10 
metagene, respectively. For visualization purposes, metagene values less than or greater 
than 2.5 times the interquartile range were removed. Comparison of expression values 
between groups was done using a Wilcoxon rank-sum test. GSEA was performed using 
the fgsea R package. Statistical significance was determined by FDR when comparing 
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between conditions and against enrichment of random gene sets when comparing across 
clusters. Gene sets for LCMV terminal exhausted T cells, progenitor exhausted T cells, 
and intratumoral ILC1 populations in Chapter 2 were curated from previously published 
reports (Gao et al., 2017; Miller et al., 2019).  
 
Multivariable classification, regression, and survival analysis 
Random forest (RF) for classification, regression, and survival analysis is a multivariable 
non-parametric ensemble partitioning tree method that can be used to model the effect of 
all interactions between genes on a response variable (Ishwaran, 2015). We used the 
randomForestSRC package version 2.5.1.14 and the following parameters: 5000 trees, 
node size of 2, and default values for mtry. The default splitting rule was used for 
classification and the log-rank slitting rule was used for survival analysis. The default value 
for nsplit was used except for models containing both two-level factor variables and 
continuous variables. In this case, the nsplit parameter was set to 2 in order to prevent 
bias against the factor-level variables. Importance scores were calculated using the 
random ensemble method. For classification problems where the two classes were 
imbalanced, a random forest quantile-classifier approach was employed. Response was 
defined as complete or partial response. All predicted values, error rates, and importance 
scores were based on cross-validation using out-of-bag samples. For variable selection 
and assessing variable robustness, we considered the set of immune cell frequencies 
(inferred by CIBERSORT), TMB, IFNG.GS, ISG.RS, and/or the difference between 
IFNG.GS and ISG.RS (dISG) in a model for immune checkpoint blockade response. Prior 
treatment status and cohort were included to ensure the lack of confounding from these 
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variables. Balanced undersampling of the majority class was performed and variable 
selection was determined using minimal depth (Ishwaran and Kogalur, 2010). The 
frequency that each variable was selected and its associated importance score were 
averaged over 100 iterations. 
To complement the RF approach for modeling probability of clinical response to immune 
checkpoint blockade, we also performed multivariable logistic regression. From this, odds 
ratios and 95% confidence intervals were determined for each log10 increase in TMB or 
0.5 unit increase in metagene expression values. To complement RF variable selection 
using minimal depth, we performed lasso regression using the glmnet R package. Both 
RF and linear regression methods yielded comparable results. 
 
High-dimensional flow cytometry analysis 
Fluorescence intensity data were analyzed using the flowCore R package and 





 T cells and NK/ILC1 cells were gated and separately analyzed. CD8
+
 
T cells were identified as TCRB
+





. For each population, an aggregate data matrix from random sampling of 1000 
events from each sample was used for dimensionality reduction and for clustering 
analysis. Clusters were identified using Phenograph (Levine et al., 2015) as implemented 
in the cytofkit R package and visualized by tSNE. Using cluster membership as class 
definitions, a RF classifier was developed using the same aggregate data matrix. After 
confirming a low misclassification error rate for each class, this RF classifier was used to 
assign all cells in all samples to one of the clusters. Using the two-dimensional tSNE 
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coordinates, a RF classifier was also developed and used to assign all cells to the tSNE 
map, allowing the distribution and frequencies of immune cells across clusters to be 
estimated for each sample. To analyze which immune clusters are strongly associated 
with wild type or IFNGR knockout tumors, the frequencies of immune cells within each 
cluster were used as features in a RF model, and the resulting importance scores were 
examined. 
 
Variant analysis of clinical lung cancer tumors 
We used previously published processed data for somatic non-synonymous variants from 
non-small cell lung cancer patients treated with anti-PD1 and anti-CTLA4 (CheckMate-
012 study) or from TCGA (Hellmann et al., 2018). Variants in one of 11 genes involved in 
type I or II IFN pathway signaling (IFNGR1, IFNGR2, IFNAR1, IFNAR2, JAK1, JAK2, 
TYK2, STAT1, STAT2, IRF9, and B2M) were examined. To exclude likely normal or 
benign variants, missense variants were annotated with ANNOVAR. Any missense variant 
found in all individuals in the ExAC database at a relative frequency greater than 0.0001 
was removed. In order to predict benign from pathogenic missense or nonsense variants, 
two algorithms for scoring deleterious variants were used that included DANN, a deep 
learning algorithm, and CADD, a machine learning algorithm. For each method, an optimal 
cut point was selected by training on ClinVar data. Here, ClinVar variants classified as 
likely benign were considered benign and those classified as likely pathogenic were 
classified as pathogenic. The optimal cut points based on ROC accuracy were then 
applied to test accuracy in predicting these labels. Any variant below the ROC cut points 
for both DANN and CADD was categorized as benign. This yielded an overall accuracy of 
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0.80, sensitivity of 0.95, and specificity of 0.54. This criterion was then applied to the TCGA 
lung cancer data and the lung cancer tumors from CheckMate-012. For indels, SIFT was 
used for evaluation and non-frameshift indels and indels predicted to be neutral were 
excluded. Examining the IFN pathway variants, any patient with at least one predicted 
pathogenic missense variant, pathogenic nonsense mutation, or deleterious indel 
resulting in a frameshift was classified as IFN pathway variant positive. 
The progression-free survival (PFS) of patients stratified by IFN pathway variant status 
was determined by Kaplan-Meier survival. The likelihood of response was determined by 
a multivariable logistic regression using variant status, log10 transformed values for TMB, 
and a previously used %PDL1 staining cut off of greater than or equal to 1%. The p-value 
for odds ratios was calculated by bootstrapping. In addition, a non-parametric model for 
response employing multivariable random forest was also used and without the need to 
transform any of the variables. The out-of-bag error rate and importance scores from this 
random forest model was then determined. To evaluate the significance of the observed 
association between IFN pathway variant status with PFS and decreased %PDL1 staining, 
the variant status of random sets of 11 genes were evaluated and used to stratify patients. 
Then, the hazard ratio for PFS and the associated p-value, and the %PDL1 staining for 
variant-positive and negative patients were recorded for 10,000 iterations and compared 
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